[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Medimaps Group\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":220},{"warningLetters":4,"total":219},[5,33,54,77,98,116,139,160,180,200],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":31,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},1663,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-01-09T14:20:00Z\">01\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-20T05:00:00Z\">12\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmimedx-group-inc-662942-12202023\">MiMedx Group, Inc.\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>23-662942\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joseph H. Capper\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MiMedx Group, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1775 W Oak Commons Court NE\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marietta\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30062\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDecember 20, 2023\u003C\u002Fp>\n\n\u003Cp>23-662942\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Capper:\u003C\u002Fp>\n\n\u003Cp>During inspections of your MiMedx Group, Inc. (hereinafter, “MiMedx”) locations at 300 Town Park Dr NW Ste 260, Kennesaw, GA 30144, and 1775 W Oak Commons Court NE, Marietta, GA 30062, conducted between February 22, 2023 and March 2, 2023, the United States Food and Drug Administration (FDA) documented your manufacture of a product derived from the placenta, AXIOFILL™, which you also refer to as “Placental Collagen Matrix” (hereinafter, “your product” or “your Placental Collagen Matrix product”). You have distributed your product directly to healthcare professionals and medical facilities throughout the United States. Your product is applied topically (for example, to “deep, irregular wounds”) and purports to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during, and after the inspections, including information on your website, www.mimedx.com, reflect that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or a condition in humans. For example, according to your product labeling, AXIOFILL™ is intended “[for] use in the replacement or supplementation of damaged or inadequate integumental tissue.” Clinical use examples referenced on your website include “trauma wounds,” “diabetic foot ulcers,” and “deep, irregular wounds.” Your product is a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of relevant materials, MiMedx does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a). Specifically, your product at minimum fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the placenta related to its utility for reconstruction, repair, or replacement.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your product, AXIOFILL™, is not the subject of an approved BLA nor is there an IND in effect for this product. Based upon this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements related to your manufacture of AXIOFILL™, including deviations from section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR Parts 210 and 211. We note that, at the time of the inspection, you had already manufactured over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of AXIOFILL™ and distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of AXIOFILL™ since September 2022.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, describing significant deviations applicable to AXIOFILL™ operations at your Town Park facility. FDA identified additional significant deviations upon further review of the information collected during this inspection, as discussed below. These deviations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug product has the identity, strength, purity, and quality it purports or is represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, your firm has manufactured and distributed AXIOFILL™ without establishing adequate written procedures to assure that your process is capable of consistently producing product that meets appropriate attributes relating to identity, quality, and purity. Namely, your written protocol, reflected in your \u003Cem>Process Performance Qualification Report for Placental Collagen Matrix (PCM)\u003C\u002Fem> (dated 2\u002F20\u002F23),is deficient in that there is no assessment of AXIOFILL™ identity, you have failed to identify tests to assess product quality, and your testing for purity is incomplete.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Process validation studies determine whether an initial state of control has been established while routine monitoring of process performance and product attributes determines whether control is maintained. Establishment of appropriate attributes relating to identity, quality, and purity of drug products is essential for assuring product quality over the product lifecycle.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> Specifically, your firm has not established laboratory controls that include appropriate final specifications for testing and release of AXIOFILL™ to assure that each batch conforms to appropriate standards of identity and purity during routine production.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. In-process control procedures are deficient in that your control procedures do not include bioburden testing [21 CFR 211.110(a)(6)].\u003C\u002Fstrong> According to your \u003Cem>Process Performance Qualification Report for Placental Collagen Matrix (PCM)\u003C\u002Fem> (effective 2\u002F20\u002F23), your firm removed \u003Cstrong>(b)(4)\u003C\u002Fstrong> bioburden testing from routine commercial production of AXIOFILL™ after completing “validation production.” Your product is \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized. In-process bioburden testing is critical for assuring that bioburden levels do not exceed the validated sterility assurance level (SAL).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Drug product samples are not representative of the entire batch [21 CFR 211.160(b)(3)].\u003C\u002Fstrong> For example, samples of AXIOFILL™ tested for residual moisture as a measure of purity per your finished product specification are not representative of the entire batch. According to CSOP220.116, \u003Cem>Product Visual Inspection\u003C\u002Fem> (revision 54, effective 12\u002F09\u002F22), only \u003Cstrong>(b)(4)\u003C\u002Fstrong> of each lot of your Placental Collagen Matrix product is collected for residual moisture testing. There are no considerations for batch size. This is not representative because, when products are lyophilized,moisture content can vary across the lot.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm has failed to conduct at least one test to verify the identity of each component of a drug product using specific identity tests, if they exist [21 CFR 211.84(d)(1)].\u003C\u002Fstrong> Specifically, your firm does not perform at least one test to verify the identity of each lot of “Placental Collagen Matrix (PCM) \u003Cstrong>(b)(4)\u003C\u002Fstrong>” using the specific identity test that exists. Although your firm indicated that the test used to determine the concentration of PCM \u003Cstrong>(b)(4)\u003C\u002Fstrong> is considered an identity test, only concentration results and not identity are reported to you by the contract laboratory. PCM \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;is used to manufacture AXIOFILL™.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Your firm failed to withhold each lot of components from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit. Your firm further failed to take representative samples of each shipment of each lot of components for testing or examination [21 CFR 211.84(a) and 21 CFR 211.84(b)].\u003C\u002Fstrong>Specifically, your firm failed to withhold each lot of PCM \u003Cstrong>(b)(4)\u003C\u002Fstrong> from use in AXIOFILL™ processing until the lot had been tested to assure compliance with your specification and released for use by your quality unit. According to your PCM \u003Cstrong>(b)(4)\u003C\u002Fstrong> specification, SPC300.034 (effective8\u002F24\u002F22), results of “composition” testing (also referred to as “concentration analysis”) are not required for release. Although your specification requires an investigation if results are failing, this procedure allows your use of components whose testing has not been reviewed prior to release, which creates the potential for your use of noncomplying components in drug processing. Additionally, according to this same specification, only \u003Cstrong>(b)(4)\u003C\u002Fstrong> from each PCM \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot received is collected for concentration analysis. Sampling is not based on the lot size, which fails to ensure that samples are representative of each lot.\u003C\u002Fp>\n\n\u003Cp>Additionally, with respect to your final specifications used for testing and release of AXIOFILL™, we have concerns that your firm has failed to include specifications for elemental impurities and endotoxin, although your firm has identified “elemental impurities from product surfaces” and endotoxin as critical quality attributes in your \u003Cem>Process Performance Qualification Report for Placental Collagen Matrix (PCM)\u003C\u002Fem> (effective 2\u002F20\u002F23).\u003C\u002Fp>\n\n\u003Cp>We are also concerned that your firm did not provide a disinfectant efficacy study for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in your processing facility and on production equipment, during the inspection, although it was requested. Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your correspondences, dated March 23, 2023 and October 23, 2023, responding to FDA’s inspectional observations on the FDA-483 issued to your Town Park facility. We have reviewed your responses and have determined that your responses are inadequate to address the deficiencies noted above. We note that “MIMEDX does not agree that the CGMP requirements are legally applicable to AXIOFILL” and that your responses contain no corrective actions directly related to the FDA-483 observations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may result in regulatory action without further notice. Such actions may include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent via email to: Jason D. Abel, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 1, email address: Jason.Abel@fda.hhs.gov. If you have any questions, please contact Jason D. Abel via email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003Cbr>\nMichael W. Roosevelt\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division I\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your product fails to meet the minimum manipulation criterion at 21 CFR 1271.10(a)(1), this letter does not further evaluate the other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Your Placental Collagen Matrix product specification indicates that your firm tests AXIOFILL™ for purity via residual moisture testing. However, purity is not limited to relative freedom from residual moisture. Refer to the definition of purity in 21 CFR 600.3(r). U.S. Food and Drug Administration Office of Biological Products Operations www.fda.gov\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\n23-662942\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoseph H. Capper\n\nRecipient Title\n\nChief Executive Officer\n\nMiMedx Group, Inc.\n\n1775 W Oak Commons Court NE\n\nMarietta, GA 30062\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nDecember 20, 2023\n\n23-662942\n\nDear Mr. Capper:\n\nDuring inspections of your MiMedx Group, Inc. (hereinafter, “MiMedx”) locations at 300 Town Park Dr NW Ste 260, Kennesaw, GA 30144, and 1775 W Oak Commons Court NE, Marietta, GA 30062, conducted between February 22, 2023 and March 2, 2023, the United States Food and Drug Administration (FDA) documented your manufacture of a product derived from the placenta, AXIOFILL™, which you also refer to as “Placental Collagen Matrix” (hereinafter, “your product” or “your Placental Collagen Matrix product”). You have distributed your product directly to healthcare professionals and medical facilities throughout the United States. Your product is applied topically (for example, to “deep, irregular wounds”) and purports to be sterile.\n\nInformation and records gathered prior to, during, and after the inspections, including information on your website, www.mimedx.com, reflect that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or a condition in humans. For example, according to your product labeling, AXIOFILL™ is intended “[for] use in the replacement or supplementation of damaged or inadequate integumental tissue.” Clinical use examples referenced on your website include “trauma wounds,” “diabetic foot ulcers,” and “deep, irregular wounds.” Your product is a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)].\n\nYour product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of relevant materials, MiMedx does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a). Specifically, your product at minimum fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the placenta related to its utility for reconstruction, repair, or replacement.1 Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271.\n\nTo lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your product, AXIOFILL™, is not the subject of an approved BLA nor is there an IND in effect for this product. Based upon this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements related to your manufacture of AXIOFILL™, including deviations from section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR Parts 210 and 211. We note that, at the time of the inspection, you had already manufactured over (b)(4) vials of AXIOFILL™ and distributed (b)(4) vials of AXIOFILL™ since September 2022.\n\nAt the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, describing significant deviations applicable to AXIOFILL™ operations at your Town Park facility. FDA identified additional significant deviations upon further review of the information collected during this inspection, as discussed below. These deviations include, but are not limited to, the following:\n\n1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug product has the identity, strength, purity, and quality it purports or is represented to possess [21 CFR 211.100(a)]. Specifically, your firm has manufactured and distributed AXIOFILL™ without establishing adequate written procedures to assure that your process is capable of consistently producing product that meets appropriate attributes relating to identity, quality, and purity. Namely, your written protocol, reflected in your Process Performance Qualification Report for Placental Collagen Matrix (PCM) (dated 2\u002F20\u002F23),is deficient in that there is no assessment of AXIOFILL™ identity, you have failed to identify tests to assess product quality, and your testing for purity is incomplete.2\n\nProcess validation studies determine whether an initial state of control has been established while routine monitoring of process performance and product attributes determines whether control is maintained. Establishment of appropriate attributes relating to identity, quality, and purity of drug products is essential for assuring product quality over the product lifecycle.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. Specifically, your firm has not established laboratory controls that include appropriate final specifications for testing and release of AXIOFILL™ to assure that each batch conforms to appropriate standards of identity and purity during routine production.\n\n3. In-process control procedures are deficient in that your control procedures do not include bioburden testing [21 CFR 211.110(a)(6)]. According to your Process Performance Qualification Report for Placental Collagen Matrix (PCM) (effective 2\u002F20\u002F23), your firm removed (b)(4) bioburden testing from routine commercial production of AXIOFILL™ after completing “validation production.” Your product is (b)(4) sterilized. In-process bioburden testing is critical for assuring that bioburden levels do not exceed the validated sterility assurance level (SAL).\n\n4. Drug product samples are not representative of the entire batch [21 CFR 211.160(b)(3)]. For example, samples of AXIOFILL™ tested for residual moisture as a measure of purity per your finished product specification are not representative of the entire batch. According to CSOP220.116, Product Visual Inspection (revision 54, effective 12\u002F09\u002F22), only (b)(4) of each lot of your Placental Collagen Matrix product is collected for residual moisture testing. There are no considerations for batch size. This is not representative because, when products are lyophilized,moisture content can vary across the lot.\n\n5. Your firm has failed to conduct at least one test to verify the identity of each component of a drug product using specific identity tests, if they exist [21 CFR 211.84(d)(1)]. Specifically, your firm does not perform at least one test to verify the identity of each lot of “Placental Collagen Matrix (PCM) (b)(4)” using the specific identity test that exists. Although your firm indicated that the test used to determine the concentration of PCM (b)(4) is considered an identity test, only concentration results and not identity are reported to you by the contract laboratory. PCM (b)(4) is used to manufacture AXIOFILL™.\n\n6. Your firm failed to withhold each lot of components from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit. Your firm further failed to take representative samples of each shipment of each lot of components for testing or examination [21 CFR 211.84(a) and 21 CFR 211.84(b)].Specifically, your firm failed to withhold each lot of PCM (b)(4) from use in AXIOFILL™ processing until the lot had been tested to assure compliance with your specification and released for use by your quality unit. According to your PCM (b)(4) specification, SPC300.034 (effective8\u002F24\u002F22), results of “composition” testing (also referred to as “concentration analysis”) are not required for release. Although your specification requires an investigation if results are failing, this procedure allows your use of components whose testing has not been reviewed prior to release, which creates the potential for your use of noncomplying components in drug processing. Additionally, according to this same specification, only (b)(4) from each PCM (b)(4) lot received is collected for concentration analysis. Sampling is not based on the lot size, which fails to ensure that samples are representative of each lot.\n\nAdditionally, with respect to your final specifications used for testing and release of AXIOFILL™, we have concerns that your firm has failed to include specifications for elemental impurities and endotoxin, although your firm has identified “elemental impurities from product surfaces” and endotoxin as critical quality attributes in your Process Performance Qualification Report for Placental Collagen Matrix (PCM) (effective 2\u002F20\u002F23).\n\nWe are also concerned that your firm did not provide a disinfectant efficacy study for (b)(4), used in your processing facility and on production equipment, during the inspection, although it was requested. Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nWe acknowledge receipt of your correspondences, dated March 23, 2023 and October 23, 2023, responding to FDA’s inspectional observations on the FDA-483 issued to your Town Park facility. We have reviewed your responses and have determined that your responses are inadequate to address the deficiencies noted above. We note that “MIMEDX does not agree that the CGMP requirements are legally applicable to AXIOFILL” and that your responses contain no corrective actions directly related to the FDA-483 observations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may result in regulatory action without further notice. Such actions may include seizure and\u002For injunction.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent via email to: Jason D. Abel, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 1, email address: Jason.Abel@fda.hhs.gov. If you have any questions, please contact Jason D. Abel via email.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division I\n\n_____________________\n\n1 Because your product fails to meet the minimum manipulation criterion at 21 CFR 1271.10(a)(1), this letter does not further evaluate the other criteria in 21 CFR 1271.10(a).\n\n2 Your Placental Collagen Matrix product specification indicates that your firm tests AXIOFILL™ for purity via residual moisture testing. However, purity is not limited to relative freedom from residual moisture. Refer to the definition of purity in 21 CFR 600.3(r). U.S. Food and Drug Administration Office of Biological Products Operations www.fda.gov","MiMedx Group, Inc.","mimedx-group-inc-662942-12202023","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmimedx-group-inc-662942-12202023","2026-10-26T08:09:25.902674+00:00","Warning Letter","Issued","2024-01-09","662942","Biologics","Joseph H. Capper","2026-08-20T00:23:12.988+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","23-662942","2023-12-20",{"id":34,"raw":35,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":24,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":20,"issuing_office":39,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":20,"reference_number":20,"action_taken_date":48,"medical_device_id":20,"response_letter_date":20},3309,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2021-06-10T16:00:00Z\">06\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-10T04:00:00Z\">06\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnova-medical-group-inc-614819-06102021\">Innova Medical Group, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Daniel J. Elliot\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Innova Medical Group, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>800 E. Colorado Blvd., Suite 288\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pasadena\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Daniel.elliott@innovamedgroup.com\"> Daniel.elliott@innovamedgroup.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CMS # 614819\u003C\u002Fp>\n\n\u003Cp>June 10, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Elliot:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, Innova Medical Group, Inc., located at 800 E. Colorado Blvd., Suite 288, Pasadena, CA from March 15 through April 9, 2021. In addition, your other manufacturing facilities at 495 N. Berry Street, Brea, CA, and MPS Medical, Inc. at 785 Challenger Street, Brea, CA, were also inspected from March 15 through April 8, 2021. During these inspections, the FDA investigators determined that your firm is a medical device manufacturer and initial distributor\u002Fimporter of the SARS-CoV-2 Antigen Rapid Qualitative Test (also distributed under the names INNOVA COVID-19 Self-Test Kit (3T Configuration), INNOVA SARS-CoV-2-Antigen Rapid Qualitative Test (7T Configuration), and INNOVA SARS-CoV-2-Antigen Rapid Qualitative Test (25T Configuration)). Based on our review, your SARS-CoV-2 Antigen Rapid Qualitative Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the SARS-CoV-2 Antigen Rapid Qualitative Test has been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, the product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to cease the sale and distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspections also revealed that the 25T Configuration and 7T Configuration of the SARS-CoV-2 Antigen Rapid Qualitative Test are misbranded within the meaning of section 502(a) of the Act, 21 U.S.C. § 352(a), in that the devices’ respective labeling was false or misleading. More specifically, the labeling distributed for your 25T Configuration devices included a “Clinical Performance” section, which claimed a Relative Sensitivity of 96% (88.75-99.17% CI); a Relative Specificity of 100% (98.34-100% CI); and an Accuracy of 98.98% (97.06-99.79% CI). This level of clinical performance for the 25T Configuration devices appears unsupported by any clinical data including both clinical performance data submitted to FDA in your Emergency Use Authorization (EUA) request for the SARS-CoV-2 Antigen Rapid Qualitative Test and in published reports of clinical studies of the SARS-CoV-2 Antigen Rapid Qualitative Test.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Similarly, the labeling distributed for your 7T Configuration devices included a “Performance of Prospective Clinical Study” section based on a prospective clinical study conducted by “third-party investigators in UK in September and October 2020” which claimed a Positive Percent Agreement of 81.4% (74.3-88.4% CI). This PPA for the 7T Configuration devices does not appear to align with the PPA observed in the phase 3b prospective clinical study conducted in the United Kingdom.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, the clinical performance estimates reported in the labeling of the 25T Configuration and 7T Configurations devices are false or misleading as they do not accurately reflect the performance estimates observed during the clinical studies of your devices.\u003C\u002Fp>\n\n\u003Cp>Separate and apart from the foregoing issues, FDA further notes that the clinical study data you submitted in your EUA request for the SARS-CoV-2 Antigen Rapid Qualitative Test was identical to data previously provided by other manufacturers in their separate EUA requests. The data reliability and accuracy issues noted herein raise significant concerns that the performance of the SARS-CoV-2 Antigen Rapid Qualitative Test has not been adequately established, and that the products distributed by Innova without FDA approval, clearance, or authorization could present a serious risk to the public health.\u003C\u002Fp>\n\n\u003Cp>The inspections also revealed that the SARS-CoV-2 Antigen Rapid Qualitative Test is adulterated with the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, is manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated April 30, 2021, from Eric Grubel, Chief Operating Officer, and the following update dated May 28, 2021, from Janet L. Michener Whipple, Interim Vice President of Quality, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on April 9, 2021. We address your responses below. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. For example:\u003C\u002Fp>\n\n\u003Cp>Our investigators observed your firm has executed contractual agreements with at least \u003Cstrong>(b)(4) \u003C\u002Fstrong>distributors for the commercial promotion and sale of the SARS-CoV-2 Antigen Rapid Qualitative Tests in the United States and has distributed more than \u003Cstrong>(b)(4) \u003C\u002Fstrong>test kits to US customers. According to your firm, these Tests have been shipped to several customers to Indiana, New York, Vermont, and Oregon during January and February of 2021. No records were maintained to demonstrate that these devices were approved for release.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge you have opened CAPA #2021-002 and created new standard operating procedures to address Purchase Management and Control and Distribution of your products, in addition to completing personnel training on the new procedures and processes. You did not provide evidence of implementation of your new SOPs, or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for incoming product and finished device acceptance activities. There are no acceptance records of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure that specified requirements for your devices are met and meets the acceptance criteria. For example,\u003C\u002Fp>\n\n\u003Cp>Your firm distributed SARS-CoV-2 Antigen Rapid Qualitative Tests. These test kits were not inspected, tested, or otherwise verified after receiving it from your contract manufacturer in China or prior to shipment to the end users. Consequently, the 7T and 3T boxes were shipped to customers with the incorrect Instructions for Use (IFU).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge you opened CAPA #2021-003 and created a new acceptance activity work instruction for incoming and finished devices, and completed personnel training on the new procedures and work instructions. You did not provide evidence of implementation of your new work instruction and evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. We also acknowledge that your firm initiated a voluntary recall of certain lots of 3T and 7T test kits distributed for non-investigational use only. It is unclear how you plan to address incorrectly labeled products distributed for investigational use. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. During the inspection, the investigators observed 13 cartons of SARS-CoV-2 Antigen Rapid Qualitative Tests co-mingled in a storage room with multiple cartons of returned nonconforming test kits, samples used for product evaluation, and damaged controls, all of which was slated for destruction. The 13 cartons of test kits were not identified as nonconforming and no records were maintained to demonstrate if an investigation was needed or the disposition of nonconforming products.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge that you opened CAPA #2021-004, and created an SOP 9.0, Control of Nonconformances, and completed personnel training on the new procedures. You did not provide adequate evidence of implementation of your new procedure or evidence demonstrating the CAPA is effective in preventing the noted violations from recurring. For example, in your May 28 response you provided the Nonconforming Incident Report, NCR #2021-002, for \u003Cstrong>(b)(4) \u003C\u002Fstrong>tests that were destroyed during the inspection. According to your incident report, an investigation to determine the root cause of the nonconforming product was not required because the “root cause is known as identified during FDA inspection” while your SOP 9.0 requires all product nonconformances to be investigated unless otherwise justified and documented. It is not clear how an FDA inspection justifies not investigating the root cause of the \u003Cstrong>(b)(4) \u003C\u002Fstrong>nonconforming tests. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, Your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: analyzing quality data sources; investigating the cause of nonconformities; identifying the action(s) needed to correct and prevent occurrence or recurrence of nonconformities; verifying or validating the CAPA to ensure the actions implemented are effective; documenting the changes in methods and procedures; disseminating information related to quality problems to appropriate individuals; and submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude the adequacy cannot be determined at this time. We acknowledge your firm has created SOP 10.0, Corrective and Preventive Action, and opened CAPA #2021-001 in accordance with your new procedure, and completed training personnel on the new procedures. However, you did not provide evidence of the effectiveness of your new CAPA procedure as the corrective actions remain in progress, and therefore we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling to ensure that complaints are processed in a uniform and timely manner, oral complaints are documented upon receipt, and complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude the adequacy cannot be determined at this time. We acknowledge that you opened CAPA #2021-006 and created SOP 14.0, Complaint Handling and Failure Investigation, and completed personnel training on the new procedures. However, your response does not indicate whether your firm will conduct a retrospective review of any complaints your firm previously received. While your response states your firm “has not received any complaints regarding its SARVS-CoV-2 Antigen Rapid Qualitative Test”, our investigators noted your storage room was holding damaged product returned from your customers, which appears to fall under section 5.6 of your new complaint procedure. You did not provide evidence of implementation of your new procedure or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for the evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. You did not evaluate your only contract manufacturer of the SARS-CoV-2 Antigen Rapid Qualitative Test system based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge your firm opened CAPA #2021-005 and created new standard operating procedures for purchase management and supplier controls, and completed personnel training on the new procedures. You did not provide evidence of the implementation of your new SOPs, or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your SARS-CoV-2 Antigen Rapid Qualitative Test is misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation include, but is not limited to:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that your firm’s response dated April 30, 2021 is not adequate. In the response, your firm noted that it developed a written MDR procedure, scheduled staff training and planned to assess the effectiveness of corrective actions by July 1. Your response included a copy of your firm’s MDR procedure titled “Medical Device Reporting (MDR and eMDR)”, Document Number: 7.0, Revision 1.0, Effective Date: 4\u002F29\u002F2021. After reviewing your firm’s MDR procedure, we noted that the procedure does not reference a process for identifying and evaluating events involving similar devices to those marketed in the United States (U.S.) as potentially reportable to FDA. Specifically, the procedure notes under the Scope section that it “applies to devices marketed in the United States”. If an event involves a similar device to one legally marketed in the U.S., it may be reportable under the MDR regulation. By not considering events involving similar legally marketed devices, potentially reportable MDRs may not be identified and evaluated for MDR decision making and submission to FDA as required by 21 CFR 803.50 and 21 CFR 803.53.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm did not provide documentation or evidence of implementation of a systematic corrective action to include a retrospective review of its adverse events in accordance with its MDR procedure.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address the violations cited in this letter. Also, federal agencies may be advised of the issuance of Warning Letters about devices and may take your compliance with Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address the violations relating to your firm’s sale or distribution of the SARS-CoV-2 Antigen Rapid Qualitative Test. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted Quality Systems and MDR reporting violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case #614819.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officers, Charles J. Chacko at 214-253-4939, or via email at charles.chacko@fda.hhs.gov or Jamie M. Bumpas at 214-253-5336, or via email at Jamie.bumpas@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&amp;C Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCc:\u003C\u002Fp>\n\n\u003Cp>Mr. Eric E. Grubel, COO\u003Cbr>\n800 E. Colorado Blvd., Suite 288\u003Cbr>\nPasadena, CA 91101\u003Cbr>\nEric.grubel@innovamedgroup.com\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See “Preliminary report from the Joint PHE Porton Down &amp; University of Oxford SARS-CoV-2 test development and validation cell: Rapid evaluation of Lateral Flow Viral Antigen detection devices (LFDs) for mass community testing:” published November 8, 2020 available at https:\u002F\u002Fwww.ox.ac.uk\u002Fsites\u002Ffiles\u002Foxford\u002Fmedia_wysiwyg\u002FUK%20evaluation_PHE%20Porton%20Down%20%20University%20of%20Oxford_final.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Id.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDaniel J. Elliot\n\nRecipient Title\n\nChief Executive Officer\n\nInnova Medical Group, Inc.\n\n800 E. Colorado Blvd., Suite 288\n\nPasadena, CA 91101\n\nUnited States\n\nDaniel.elliott@innovamedgroup.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 614819\n\nJune 10, 2021\n\nDear Mr. Elliot:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, Innova Medical Group, Inc., located at 800 E. Colorado Blvd., Suite 288, Pasadena, CA from March 15 through April 9, 2021. In addition, your other manufacturing facilities at 495 N. Berry Street, Brea, CA, and MPS Medical, Inc. at 785 Challenger Street, Brea, CA, were also inspected from March 15 through April 8, 2021. During these inspections, the FDA investigators determined that your firm is a medical device manufacturer and initial distributor\u002Fimporter of the SARS-CoV-2 Antigen Rapid Qualitative Test (also distributed under the names INNOVA COVID-19 Self-Test Kit (3T Configuration), INNOVA SARS-CoV-2-Antigen Rapid Qualitative Test (7T Configuration), and INNOVA SARS-CoV-2-Antigen Rapid Qualitative Test (25T Configuration)). Based on our review, your SARS-CoV-2 Antigen Rapid Qualitative Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the SARS-CoV-2 Antigen Rapid Qualitative Test has been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, the product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to cease the sale and distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”4 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspections also revealed that the 25T Configuration and 7T Configuration of the SARS-CoV-2 Antigen Rapid Qualitative Test are misbranded within the meaning of section 502(a) of the Act, 21 U.S.C. § 352(a), in that the devices’ respective labeling was false or misleading. More specifically, the labeling distributed for your 25T Configuration devices included a “Clinical Performance” section, which claimed a Relative Sensitivity of 96% (88.75-99.17% CI); a Relative Specificity of 100% (98.34-100% CI); and an Accuracy of 98.98% (97.06-99.79% CI). This level of clinical performance for the 25T Configuration devices appears unsupported by any clinical data including both clinical performance data submitted to FDA in your Emergency Use Authorization (EUA) request for the SARS-CoV-2 Antigen Rapid Qualitative Test and in published reports of clinical studies of the SARS-CoV-2 Antigen Rapid Qualitative Test.5 Similarly, the labeling distributed for your 7T Configuration devices included a “Performance of Prospective Clinical Study” section based on a prospective clinical study conducted by “third-party investigators in UK in September and October 2020” which claimed a Positive Percent Agreement of 81.4% (74.3-88.4% CI). This PPA for the 7T Configuration devices does not appear to align with the PPA observed in the phase 3b prospective clinical study conducted in the United Kingdom.6 Accordingly, the clinical performance estimates reported in the labeling of the 25T Configuration and 7T Configurations devices are false or misleading as they do not accurately reflect the performance estimates observed during the clinical studies of your devices.\n\nSeparate and apart from the foregoing issues, FDA further notes that the clinical study data you submitted in your EUA request for the SARS-CoV-2 Antigen Rapid Qualitative Test was identical to data previously provided by other manufacturers in their separate EUA requests. The data reliability and accuracy issues noted herein raise significant concerns that the performance of the SARS-CoV-2 Antigen Rapid Qualitative Test has not been adequately established, and that the products distributed by Innova without FDA approval, clearance, or authorization could present a serious risk to the public health.\n\nThe inspections also revealed that the SARS-CoV-2 Antigen Rapid Qualitative Test is adulterated with the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, is manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated April 30, 2021, from Eric Grubel, Chief Operating Officer, and the following update dated May 28, 2021, from Janet L. Michener Whipple, Interim Vice President of Quality, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on April 9, 2021. We address your responses below. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. For example:\n\nOur investigators observed your firm has executed contractual agreements with at least (b)(4) distributors for the commercial promotion and sale of the SARS-CoV-2 Antigen Rapid Qualitative Tests in the United States and has distributed more than (b)(4) test kits to US customers. According to your firm, these Tests have been shipped to several customers to Indiana, New York, Vermont, and Oregon during January and February of 2021. No records were maintained to demonstrate that these devices were approved for release.\n\nWe reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge you have opened CAPA #2021-002 and created new standard operating procedures to address Purchase Management and Control and Distribution of your products, in addition to completing personnel training on the new procedures and processes. You did not provide evidence of implementation of your new SOPs, or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\n\n2. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm has not established procedures for incoming product and finished device acceptance activities. There are no acceptance records of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure that specified requirements for your devices are met and meets the acceptance criteria. For example,\n\nYour firm distributed SARS-CoV-2 Antigen Rapid Qualitative Tests. These test kits were not inspected, tested, or otherwise verified after receiving it from your contract manufacturer in China or prior to shipment to the end users. Consequently, the 7T and 3T boxes were shipped to customers with the incorrect Instructions for Use (IFU).\n\nWe reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge you opened CAPA #2021-003 and created a new acceptance activity work instruction for incoming and finished devices, and completed personnel training on the new procedures and work instructions. You did not provide evidence of implementation of your new work instruction and evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. We also acknowledge that your firm initiated a voluntary recall of certain lots of 3T and 7T test kits distributed for non-investigational use only. It is unclear how you plan to address incorrectly labeled products distributed for investigational use. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\n\n3. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established and maintained procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. During the inspection, the investigators observed 13 cartons of SARS-CoV-2 Antigen Rapid Qualitative Tests co-mingled in a storage room with multiple cartons of returned nonconforming test kits, samples used for product evaluation, and damaged controls, all of which was slated for destruction. The 13 cartons of test kits were not identified as nonconforming and no records were maintained to demonstrate if an investigation was needed or the disposition of nonconforming products.\n\nWe reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge that you opened CAPA #2021-004, and created an SOP 9.0, Control of Nonconformances, and completed personnel training on the new procedures. You did not provide adequate evidence of implementation of your new procedure or evidence demonstrating the CAPA is effective in preventing the noted violations from recurring. For example, in your May 28 response you provided the Nonconforming Incident Report, NCR #2021-002, for (b)(4) tests that were destroyed during the inspection. According to your incident report, an investigation to determine the root cause of the nonconforming product was not required because the “root cause is known as identified during FDA inspection” while your SOP 9.0 requires all product nonconformances to be investigated unless otherwise justified and documented. It is not clear how an FDA inspection justifies not investigating the root cause of the (b)(4) nonconforming tests. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\n\n4. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, Your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: analyzing quality data sources; investigating the cause of nonconformities; identifying the action(s) needed to correct and prevent occurrence or recurrence of nonconformities; verifying or validating the CAPA to ensure the actions implemented are effective; documenting the changes in methods and procedures; disseminating information related to quality problems to appropriate individuals; and submitting relevant information on quality problems for management review.\n\nWe reviewed your firm’s response and conclude the adequacy cannot be determined at this time. We acknowledge your firm has created SOP 10.0, Corrective and Preventive Action, and opened CAPA #2021-001 in accordance with your new procedure, and completed training personnel on the new procedures. However, you did not provide evidence of the effectiveness of your new CAPA procedure as the corrective actions remain in progress, and therefore we are unable to fully assess the adequacy of your response.\n\n5. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling to ensure that complaints are processed in a uniform and timely manner, oral complaints are documented upon receipt, and complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\nWe reviewed your firm’s response and conclude the adequacy cannot be determined at this time. We acknowledge that you opened CAPA #2021-006 and created SOP 14.0, Complaint Handling and Failure Investigation, and completed personnel training on the new procedures. However, your response does not indicate whether your firm will conduct a retrospective review of any complaints your firm previously received. While your response states your firm “has not received any complaints regarding its SARVS-CoV-2 Antigen Rapid Qualitative Test”, our investigators noted your storage room was holding damaged product returned from your customers, which appears to fall under section 5.6 of your new complaint procedure. You did not provide evidence of implementation of your new procedure or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\n\n6. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for the evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. You did not evaluate your only contract manufacturer of the SARS-CoV-2 Antigen Rapid Qualitative Test system based on their ability to meet specified requirements, including quality requirements.\n\nWe reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge your firm opened CAPA #2021-005 and created new standard operating procedures for purchase management and supplier controls, and completed personnel training on the new procedures. You did not provide evidence of the implementation of your new SOPs, or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\n\nOur inspection also revealed that your SARS-CoV-2 Antigen Rapid Qualitative Test is misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation include, but is not limited to:\n\n7. Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nWe reviewed your firm’s response and conclude that your firm’s response dated April 30, 2021 is not adequate. In the response, your firm noted that it developed a written MDR procedure, scheduled staff training and planned to assess the effectiveness of corrective actions by July 1. Your response included a copy of your firm’s MDR procedure titled “Medical Device Reporting (MDR and eMDR)”, Document Number: 7.0, Revision 1.0, Effective Date: 4\u002F29\u002F2021. After reviewing your firm’s MDR procedure, we noted that the procedure does not reference a process for identifying and evaluating events involving similar devices to those marketed in the United States (U.S.) as potentially reportable to FDA. Specifically, the procedure notes under the Scope section that it “applies to devices marketed in the United States”. If an event involves a similar device to one legally marketed in the U.S., it may be reportable under the MDR regulation. By not considering events involving similar legally marketed devices, potentially reportable MDRs may not be identified and evaluated for MDR decision making and submission to FDA as required by 21 CFR 803.50 and 21 CFR 803.53.\n\nAdditionally, your firm did not provide documentation or evidence of implementation of a systematic corrective action to include a retrospective review of its adverse events in accordance with its MDR procedure.\n\nYour firm should take prompt action to address the violations cited in this letter. Also, federal agencies may be advised of the issuance of Warning Letters about devices and may take your compliance with Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address the violations relating to your firm’s sale or distribution of the SARS-CoV-2 Antigen Rapid Qualitative Test. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted Quality Systems and MDR reporting violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case #614819.\n\nIf you have questions about the contents of this letter, please contact Compliance Officers, Charles J. Chacko at 214-253-4939, or via email at charles.chacko@fda.hhs.gov or Jamie M. Bumpas at 214-253-5336, or via email at Jamie.bumpas@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&C Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and Radiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nCc:\n\nMr. Eric E. Grubel, COO\n\n800 E. Colorado Blvd., Suite 288\n\nPasadena, CA 91101\n\nEric.grubel@innovamedgroup.com\n\n__________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.\n\n5 See “Preliminary report from the Joint PHE Porton Down & University of Oxford SARS-CoV-2 test development and validation cell: Rapid evaluation of Lateral Flow Viral Antigen detection devices (LFDs) for mass community testing:” published November 8, 2020 available at https:\u002F\u002Fwww.ox.ac.uk\u002Fsites\u002Ffiles\u002Foxford\u002Fmedia_wysiwyg\u002FUK%20evaluation_PHE%20Porton%20Down%20%20University%20of%20Oxford_final.pdf.\n\n6 Id.","Innova Medical Group, Inc.","innova-medical-group-inc-614819-06102021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnova-medical-group-inc-614819-06102021","2026-10-26T08:08:59.098007+00:00","2021-06-10","614819","Medical Devices","Daniel J. Elliot","2026-08-20T03:04:36.988+00:00","VIA Electronic Mail",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":20,"letter_url":67,"updated_at":68,"action_type":23,"case_status":24,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":20,"issuing_office":60,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":20,"reference_number":75,"action_taken_date":76,"medical_device_id":20,"response_letter_date":20},1147,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2024-12-03T14:20:00Z\">12\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-08T04:00:00Z\">08\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmena-food-group-llc-673814-08082024\">Mena Food Group, LLC\u003C\u002Fa>","Office of Regulatory Affairs","CGMP\u002FManufacturing, Packing or Holding Human Food\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>24-HAFE4-WL-04\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. David Mena\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mena Food Group, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4710 NW 15th Ave Ste 5a-2\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Lauderdale\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33309-3785\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:david@bakerymilitellos.co\"> david@bakerymilitellos.co\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Regulatory Affairs\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>24-HAFE4-WL-04 \u002F CMS No. 673814\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mena:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility located at 4710 NW 15th Ave Ste 5a-2, Fort Lauderdale, FL from October 30, 2023, to November 20, 2023. Your facility manufactures ready-to eat (RTE) bakery products including breads, cakes, and pastries. During our inspection of your facility, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we determined that your food products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. § 342(a)(4)) in that they were prepared, packed or held under insanitary conditions whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act (21 U.S.C. § 331(uu)).\u003C\u002Fp>\n\n\u003Cp>Furthermore, during this inspection, our investigators obtained product labeling and ingredient information for several of your RTE bakery products. We have reviewed these documents and found the products that you manufacture and distribute are not labeled in accordance with the Code of Federal Regulations, Title 21, Part 101, Food Labeling Regulation (21 CFR Part 101). Therefore, your RTE bakery products are misbranded within the meaning of Section 403 of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 343, in that they are not labeled with the mandatory information required by the Act.\u003C\u002Fp>\n\n\u003Cp>You may find the Act and further information about the CGMP &amp; PC rule through links in FDA's home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing the deviations found at your firm. However, to date, we have not received your written response to the issued FDA 483 describing corrective actions taken by your firm. We are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (Subpart C):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You did not identify and evaluate a known or reasonably foreseeable hazard to determine whether it required a preventive control for your RTE breads, cakes, and pastries, as required by 21 CFR 117.130(a)(1). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. You did not identify and evaluate recontamination with environmental pathogens as a known or reasonably foreseeable hazard to determine whether it requires a preventive control. Your RTE bakery products are exposed to the environment at post-baking steps at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> steps where they can be contaminated with environmental pathogens such as \u003Cem>Salmonella\u003C\u002Fem> and \u003Cem>Listeria monocytogenes\u003C\u002Fem>. The packaged bakery products do not receive a lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize pathogens. Therefore, contamination with environmental pathogens is a known or reasonably foreseeable hazard. Further, a knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens as requiring a preventive control. Preventive controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens (see 21 CFR 117.135(c)(3)).\u003C\u002Fp>\n\n\u003Cp>In addition, note that environmental monitoring is required if contamination of an RTE food with an environmental pathogen is a hazard requiring a preventive control (see 21 CFR 117.165(a)(3)). Your facility is not monitoring the environment for an environmental pathogen, or for an appropriate indicator organism, to verify the effectiveness of your sanitation controls.\u003C\u002Fp>\n\n\u003Cp>b. You did not identify and evaluate mycotoxins as a known or reasonably foreseeable hazard to determine whether they require a preventive control. Your facility manufactures RTE bakery products (e.g., breads) containing high protein wheat flour, which has been associated with mycotoxins such as deoxynivalenol (DON). Therefore, mycotoxins are a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify mycotoxins as a hazard requiring a preventive control in this ingredient. Further, a facility that identifies raw materials and other ingredients that require a supply-chain-applied control, such as mycotoxins, must establish and implement a risk-based supply-chain program for those raw materials and ingredients (see 21 CFR 117.405(a)(1)). The supply-chain program must include using approved suppliers and conducting supplier verification activities (see 21 CFR 117.410). You do not have this program in place.\u003C\u002Fp>\n\n\u003Cp>2. You did not appropriately evaluate a known or reasonably foreseeable hazard to determine whether it required a preventive control in your RTE breads, cakes, and pastries, as required by 21 CFR 117.130(a)(1). Specifically, your facility’s written hazard analysis considered undeclared allergens; however, you determined this to be the responsibility of your customer and the consumer. Your facility manufactures finished products that contain allergens such as wheat, milk, egg, soy (soybean lecithin), coconut, walnuts, and sesame. They are distributed to restaurants, hotels, nursing homes, hospitals, and distributors\u002Fwholesalers with labeling that does not include an ingredient statement and allergen declaration. Foods containing allergens can cause serious adverse health consequences or death to allergic individuals if they consume a food to which they are allergic. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify food allergens as hazards requiring a preventive control. Preventive controls for food allergens include procedures, practices, and processes employed for labeling to ensure that all food allergens are included on the label (see 21 CFR 117.135(c)(2)(ii)). We note the following with regard to your allergen labeling:\u003C\u002Fp>\n\n\u003Cp>a. On November 13, 3023, challah burger buns, challah knot rolls, and sesame challah burger buns were staged for distribution in your staging area. They were packaged in pre-printed plastic bags without the wheat, soy, and sesame allergens declared.\u003C\u002Fp>\n\n\u003Cp>b. On November 13, 3023, 12-inch hoagie rolls were staged for distribution in your staging area. They were packaged in clear plastic bags that did not declare wheat and soy allergens.\u003C\u002Fp>\n\n\u003Cp>3. Your allergen controls procedures for nuts do not ensure protection of food from allergen cross-contact from walnuts, as required by 21 CFR 117.135(c)(2)(i). Specifically, your hazard analysis for various RTE breads, cakes, and pastries identified the hazard of allergen cross-contact at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> steps. At these steps, you use shared food-contact equipment and utensils to manufacture bakery products containing different allergen profiles on the same day. However, your written preventive control program procedures do not include monitoring, corrective actions, and verification to control the hazard and you do not have records documenting activities performed. In addition, your allergen procedures for nuts do not include coconut, which is an allergen.\u003C\u002Fp>\n\n\u003Cp>In addition, your written allergen preventive control procedure states that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. However, this procedure was not followed. On October 30, 2023, the rotating round turntable and utensils used by your employee were not cleaned after handling the RTE pina colada cake (containing wheat, soy, eggs, milk and coconut) and before handling the RTE mocha cake (containing wheat, soy, eggs, and milk but not coconut).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (Subpart B):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You did not take reasonable measures and precautions to ensure that all persons working in direct contract with food, food-contact surfaces, and food packaging materials conform to hygienic practices while on duty to the extent necessary to protect against allergen cross-contact and against contamination of food, as required by 21 CFR 117.10(b). Specifically, on October 30, 2023, during the manufacturing of various RTE breads, cakes, and pastries:\u003C\u002Fp>\n\n\u003Cp>a. A pastry area employee walked outside the firm to her car wearing her hairnet and plastic work apron. She returned to the pastry area without washing her hands or replacing her hairnet and plastic apron.\u003C\u002Fp>\n\n\u003Cp>b. A cake room employee wearing a hairnet, gloves, and plastic apron was observed preparing raw chocolate cigars. He exited the cake room door leading to the outside. A few moments later he returned through the same exterior door wearing a hairnet, gloves, apron, and the facemask. He immediately returned to preparing raw chocolate cigars without washing his hands and changing his hairnet, gloves, and plastic apron.\u003C\u002Fp>\n\n\u003Cp>c. A bearded pastry area employee mixing RTE frosting\u002Ficing was using his gloved hand to transfer the frosting to another bowl. While he was transferring the frosting, part of his bare arm\u002Farm hair came in direct contact with the frosting. Also, this employee was wearing a beard cover; however, it was pulled down under his chin during the transferring of the frosting.\u003C\u002Fp>\n\n\u003Cp>d. In your pastry room and cake room, employees did not wash their hands or gloves after touching their face.\u003C\u002Fp>\n\n\u003Cp>e. Open beverage bottles were observed:\u003C\u002Fp>\n\n\u003Cp>&nbsp; 1) In the bread processing area, under the preparation tables, while the employees were manipulating raw dough.\u003Cbr>\n&nbsp; 2) In the pastry area, under preparation tables, while the employees were manipulating in-process products.\u003Cbr>\n&nbsp; 3) Inside the pastry area reach-in freezer, where ingredients, in-process, and finished products are stored.\u003C\u002Fp>\n\n\u003Cp>f. In your cake room, your facility has a black multi-drawer toolbox where utensils (e.g., spatulas, knives, cake cutting wire) are stored after they are cleaned. These utensils are taken from the toolbox and immediately used to decorate and cut RTE cake room products. The toolbox contained personal items such as glasses, keys, and opened beverage bottles.\u003C\u002Fp>\n\n\u003Cp>2. You did not maintain your plant in a clean and sanitary condition and in adequate repair, as required by 21 CFR 117.35(a). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Your firm assembles RTE cakes and pastry items inside the cake room. On October 30, 2023, the fluorescent light located directly above the processing tables appeared to have a black mold-like substance on the light diffusers. Adjacent ceiling tiles were also observed with an apparent similar substance.\u003C\u002Fp>\n\n\u003Cp>b. On October 30, 2023, two large fans in the cutting and packing room were observed to have excessive filth and debris on the metal wire fan guard. You use these fans to help cool down the RTE baked products. The fans were observed blowing onto RTE uncovered cupcakes on a pan rack cart.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding Violations:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Your Assorted Cupcakes, Challah Burger Buns with Sesame, Challah Hoagies, and Chocolate Peanut Butter Cake products are misbranded within the meaning of Section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product labels fail to declare individual major food allergens, as required by section 403(w)(1) of the Act.\u003C\u002Fp>\n\n\u003Cp>Section 201(qq) of the Act [21 U.S.C. § 321(qq)], defines milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, soybeans, and sesame as well as any food ingredient that contains protein derived from one of these foods, with the exception of highly refined oils as “major food allergens.” A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\u003C\u002Fli>\n\t\u003Cli>The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., “Whey (Milk)”), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Specifically, your Assorted Cupcakes product is manufactured with milk, soy, egg, and wheat. Your Challah Burger Buns with Sesame and Challah Hoagies products are manufactured with wheat and soy. The Challah Burger Buns with Sesame are further manufactured with sesame. Your Chocolate Peanut Butter Cake product is manufactured with, at minimum, peanuts, and potentially other major food allergens. These major food allergens are not listed on your finished product labels.\u003C\u002Fp>\n\n\u003Cp>2. Your Assorted Cupcakes Challah Burger Buns with Sesame, Challah Hoagies, and Chocolate Peanut Butter Cake products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the products are fabricated from two or more ingredients and the common or usual name of each ingredient and sub-ingredient is not declared on the label, as required under 21 CFR 101.4. Specifically, these products are not labeled with an ingredient statement.\u003C\u002Fp>\n\n\u003Cp>3. Your Assorted Cupcakes product is misbranded within the meaning of section 403(k) of the Act [21 U.S.C. §343(k)] in that the vanilla cupcakes and frostings used for both vanilla and chocolate cupcakes contain color additives, but the label fails to declare the presence of color additives as required by 21 CFR 101.22(k).\u003C\u002Fp>\n\n\u003Cp>4. Your Challah Burger Buns with Sesame and Challah Hoagies products are misbranded within the meaning of section 403(i)(1) of the Act [21 U.S.C. § 343(i)(1)] in that the product labels, if any, fail to bear the common or usual name of the food as required by 21 CFR 101.3.\u003C\u002Fp>\n\n\u003Cp>5. Your Assorted Cupcakes, Challah Burger Buns with Sesame, Challah Hoagies, and Chocolate Peanut Butter Cake products are misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343(e)(1)] in that the product labels fail to include the place of business of the manufacturer, packer, or distributor, as required by 21 CFR 101.5(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your Assorted Cupcakes and Chocolate Peanut Butter Cake products are labeled with your firm’s dba name but not the street address, city, state, or ZIP code. Your Challah Burger Buns with Sesame and Challah Hoagies are not labeled.\u003C\u002Fp>\n\n\u003Cp>We note that the street address may be omitted if it is shown in a current city directory or telephone directory. Further, in the case of non-consumer packages, the requirement for listing the zip code may be met with declaration on the label or on the labeling (including invoice).\u003C\u002Fp>\n\n\u003Cp>6. Your Assorted Cupcakes, Challah Burger Buns with Sesame, Challah Hoagies, and Chocolate Peanut Butter Cake products are misbranded within the meaning of Section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because they fail to bear an accurate statement of the net quantity of contents, as required by 21 CFR 101.7.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comment regarding your Assorted Cupcakes product: “Cupcakes Asst” is not an appropriate common or usual name for the product as required by 21 CFR 101.3.\u003C\u002Fp>\n\n\u003Cp>Your written response should be directed to the U.S. Food and Drug Administration, attention to: Mr. Ramon A. Hernandez, Program Division Director, HAFE4, 466 Ave. Fernández Juncos, San Juan, Puerto Rico 00901-3223. You may email a copy of your response with appropriate attachments to the email address: orahafeast4firmresponses@fda.hhs.gov. If you have any questions regarding this letter, please contact, Ms. Gina Eng, Compliance Officer, at (240) 753-3935 or via email at Gina.Eng@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ramon A. Hernandez\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast IV Division\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nElectronic Mail\n\nReference #:\n\n24-HAFE4-WL-04\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. David Mena\n\nRecipient Title\n\nOwner\u002FPresident\n\nMena Food Group, LLC\n\n4710 NW 15th Ave Ste 5a-2\n\nFort Lauderdale, FL 33309-3785\n\nUnited States\n\ndavid@bakerymilitellos.co\n\nIssuing Office:\n\nOffice of Regulatory Affairs\n\nUnited States\n\nWARNING LETTER\n\n24-HAFE4-WL-04 \u002F CMS No. 673814\n\nDear Mr. Mena:\n\nThe United States Food and Drug Administration (FDA) inspected your facility located at 4710 NW 15th Ave Ste 5a-2, Fort Lauderdale, FL from October 30, 2023, to November 20, 2023. Your facility manufactures ready-to eat (RTE) bakery products including breads, cakes, and pastries. During our inspection of your facility, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\n\nBased on FDA’s inspectional findings, we determined that your food products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. § 342(a)(4)) in that they were prepared, packed or held under insanitary conditions whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act (21 U.S.C. § 331(uu)).\n\nFurthermore, during this inspection, our investigators obtained product labeling and ingredient information for several of your RTE bakery products. We have reviewed these documents and found the products that you manufacture and distribute are not labeled in accordance with the Code of Federal Regulations, Title 21, Part 101, Food Labeling Regulation (21 CFR Part 101). Therefore, your RTE bakery products are misbranded within the meaning of Section 403 of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 343, in that they are not labeled with the mandatory information required by the Act.\n\nYou may find the Act and further information about the CGMP & PC rule through links in FDA's home page at http:\u002F\u002Fwww.fda.gov.\n\nAt the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing the deviations found at your firm. However, to date, we have not received your written response to the issued FDA 483 describing corrective actions taken by your firm. We are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility.\n\nHazard Analysis and Risk-Based Preventive Controls (Subpart C):\n\n1. You did not identify and evaluate a known or reasonably foreseeable hazard to determine whether it required a preventive control for your RTE breads, cakes, and pastries, as required by 21 CFR 117.130(a)(1). Specifically:\n\na. You did not identify and evaluate recontamination with environmental pathogens as a known or reasonably foreseeable hazard to determine whether it requires a preventive control. Your RTE bakery products are exposed to the environment at post-baking steps at the (b)(4) steps where they can be contaminated with environmental pathogens such as Salmonella and Listeria monocytogenes. The packaged bakery products do not receive a lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize pathogens. Therefore, contamination with environmental pathogens is a known or reasonably foreseeable hazard. Further, a knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens as requiring a preventive control. Preventive controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens (see 21 CFR 117.135(c)(3)).\n\nIn addition, note that environmental monitoring is required if contamination of an RTE food with an environmental pathogen is a hazard requiring a preventive control (see 21 CFR 117.165(a)(3)). Your facility is not monitoring the environment for an environmental pathogen, or for an appropriate indicator organism, to verify the effectiveness of your sanitation controls.\n\nb. You did not identify and evaluate mycotoxins as a known or reasonably foreseeable hazard to determine whether they require a preventive control. Your facility manufactures RTE bakery products (e.g., breads) containing high protein wheat flour, which has been associated with mycotoxins such as deoxynivalenol (DON). Therefore, mycotoxins are a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify mycotoxins as a hazard requiring a preventive control in this ingredient. Further, a facility that identifies raw materials and other ingredients that require a supply-chain-applied control, such as mycotoxins, must establish and implement a risk-based supply-chain program for those raw materials and ingredients (see 21 CFR 117.405(a)(1)). The supply-chain program must include using approved suppliers and conducting supplier verification activities (see 21 CFR 117.410). You do not have this program in place.\n\n2. You did not appropriately evaluate a known or reasonably foreseeable hazard to determine whether it required a preventive control in your RTE breads, cakes, and pastries, as required by 21 CFR 117.130(a)(1). Specifically, your facility’s written hazard analysis considered undeclared allergens; however, you determined this to be the responsibility of your customer and the consumer. Your facility manufactures finished products that contain allergens such as wheat, milk, egg, soy (soybean lecithin), coconut, walnuts, and sesame. They are distributed to restaurants, hotels, nursing homes, hospitals, and distributors\u002Fwholesalers with labeling that does not include an ingredient statement and allergen declaration. Foods containing allergens can cause serious adverse health consequences or death to allergic individuals if they consume a food to which they are allergic. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify food allergens as hazards requiring a preventive control. Preventive controls for food allergens include procedures, practices, and processes employed for labeling to ensure that all food allergens are included on the label (see 21 CFR 117.135(c)(2)(ii)). We note the following with regard to your allergen labeling:\n\na. On November 13, 3023, challah burger buns, challah knot rolls, and sesame challah burger buns were staged for distribution in your staging area. They were packaged in pre-printed plastic bags without the wheat, soy, and sesame allergens declared.\n\nb. On November 13, 3023, 12-inch hoagie rolls were staged for distribution in your staging area. They were packaged in clear plastic bags that did not declare wheat and soy allergens.\n\n3. Your allergen controls procedures for nuts do not ensure protection of food from allergen cross-contact from walnuts, as required by 21 CFR 117.135(c)(2)(i). Specifically, your hazard analysis for various RTE breads, cakes, and pastries identified the hazard of allergen cross-contact at the (b)(4) steps. At these steps, you use shared food-contact equipment and utensils to manufacture bakery products containing different allergen profiles on the same day. However, your written preventive control program procedures do not include monitoring, corrective actions, and verification to control the hazard and you do not have records documenting activities performed. In addition, your allergen procedures for nuts do not include coconut, which is an allergen.\n\nIn addition, your written allergen preventive control procedure states that “(b)(4)”. However, this procedure was not followed. On October 30, 2023, the rotating round turntable and utensils used by your employee were not cleaned after handling the RTE pina colada cake (containing wheat, soy, eggs, milk and coconut) and before handling the RTE mocha cake (containing wheat, soy, eggs, and milk but not coconut).\n\nCurrent Good Manufacturing Practice (Subpart B):\n\n1. You did not take reasonable measures and precautions to ensure that all persons working in direct contract with food, food-contact surfaces, and food packaging materials conform to hygienic practices while on duty to the extent necessary to protect against allergen cross-contact and against contamination of food, as required by 21 CFR 117.10(b). Specifically, on October 30, 2023, during the manufacturing of various RTE breads, cakes, and pastries:\n\na. A pastry area employee walked outside the firm to her car wearing her hairnet and plastic work apron. She returned to the pastry area without washing her hands or replacing her hairnet and plastic apron.\n\nb. A cake room employee wearing a hairnet, gloves, and plastic apron was observed preparing raw chocolate cigars. He exited the cake room door leading to the outside. A few moments later he returned through the same exterior door wearing a hairnet, gloves, apron, and the facemask. He immediately returned to preparing raw chocolate cigars without washing his hands and changing his hairnet, gloves, and plastic apron.\n\nc. A bearded pastry area employee mixing RTE frosting\u002Ficing was using his gloved hand to transfer the frosting to another bowl. While he was transferring the frosting, part of his bare arm\u002Farm hair came in direct contact with the frosting. Also, this employee was wearing a beard cover; however, it was pulled down under his chin during the transferring of the frosting.\n\nd. In your pastry room and cake room, employees did not wash their hands or gloves after touching their face.\n\ne. Open beverage bottles were observed:\n\n1) In the bread processing area, under the preparation tables, while the employees were manipulating raw dough.\n\n2) In the pastry area, under preparation tables, while the employees were manipulating in-process products.\n\n3) Inside the pastry area reach-in freezer, where ingredients, in-process, and finished products are stored.\n\nf. In your cake room, your facility has a black multi-drawer toolbox where utensils (e.g., spatulas, knives, cake cutting wire) are stored after they are cleaned. These utensils are taken from the toolbox and immediately used to decorate and cut RTE cake room products. The toolbox contained personal items such as glasses, keys, and opened beverage bottles.\n\n2. You did not maintain your plant in a clean and sanitary condition and in adequate repair, as required by 21 CFR 117.35(a). Specifically:\n\na. Your firm assembles RTE cakes and pastry items inside the cake room. On October 30, 2023, the fluorescent light located directly above the processing tables appeared to have a black mold-like substance on the light diffusers. Adjacent ceiling tiles were also observed with an apparent similar substance.\n\nb. On October 30, 2023, two large fans in the cutting and packing room were observed to have excessive filth and debris on the metal wire fan guard. You use these fans to help cool down the RTE baked products. The fans were observed blowing onto RTE uncovered cupcakes on a pan rack cart.\n\nMisbranding Violations:\n\n1. Your Assorted Cupcakes, Challah Burger Buns with Sesame, Challah Hoagies, and Chocolate Peanut Butter Cake products are misbranded within the meaning of Section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product labels fail to declare individual major food allergens, as required by section 403(w)(1) of the Act.\n\nSection 201(qq) of the Act [21 U.S.C. § 321(qq)], defines milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, soybeans, and sesame as well as any food ingredient that contains protein derived from one of these foods, with the exception of highly refined oils as “major food allergens.” A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\n\nThe word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\n\nThe common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., “Whey (Milk)”), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\n\nSpecifically, your Assorted Cupcakes product is manufactured with milk, soy, egg, and wheat. Your Challah Burger Buns with Sesame and Challah Hoagies products are manufactured with wheat and soy. The Challah Burger Buns with Sesame are further manufactured with sesame. Your Chocolate Peanut Butter Cake product is manufactured with, at minimum, peanuts, and potentially other major food allergens. These major food allergens are not listed on your finished product labels.\n\n2. Your Assorted Cupcakes Challah Burger Buns with Sesame, Challah Hoagies, and Chocolate Peanut Butter Cake products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the products are fabricated from two or more ingredients and the common or usual name of each ingredient and sub-ingredient is not declared on the label, as required under 21 CFR 101.4. Specifically, these products are not labeled with an ingredient statement.\n\n3. Your Assorted Cupcakes product is misbranded within the meaning of section 403(k) of the Act [21 U.S.C. §343(k)] in that the vanilla cupcakes and frostings used for both vanilla and chocolate cupcakes contain color additives, but the label fails to declare the presence of color additives as required by 21 CFR 101.22(k).\n\n4. Your Challah Burger Buns with Sesame and Challah Hoagies products are misbranded within the meaning of section 403(i)(1) of the Act [21 U.S.C. § 343(i)(1)] in that the product labels, if any, fail to bear the common or usual name of the food as required by 21 CFR 101.3.\n\n5. Your Assorted Cupcakes, Challah Burger Buns with Sesame, Challah Hoagies, and Chocolate Peanut Butter Cake products are misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343(e)(1)] in that the product labels fail to include the place of business of the manufacturer, packer, or distributor, as required by 21 CFR 101.5(a).\n\nSpecifically, your Assorted Cupcakes and Chocolate Peanut Butter Cake products are labeled with your firm’s dba name but not the street address, city, state, or ZIP code. Your Challah Burger Buns with Sesame and Challah Hoagies are not labeled.\n\nWe note that the street address may be omitted if it is shown in a current city directory or telephone directory. Further, in the case of non-consumer packages, the requirement for listing the zip code may be met with declaration on the label or on the labeling (including invoice).\n\n6. Your Assorted Cupcakes, Challah Burger Buns with Sesame, Challah Hoagies, and Chocolate Peanut Butter Cake products are misbranded within the meaning of Section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because they fail to bear an accurate statement of the net quantity of contents, as required by 21 CFR 101.7.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nWe also offer the following comment regarding your Assorted Cupcakes product: “Cupcakes Asst” is not an appropriate common or usual name for the product as required by 21 CFR 101.3.\n\nYour written response should be directed to the U.S. Food and Drug Administration, attention to: Mr. Ramon A. Hernandez, Program Division Director, HAFE4, 466 Ave. Fernández Juncos, San Juan, Puerto Rico 00901-3223. You may email a copy of your response with appropriate attachments to the email address: orahafeast4firmresponses@fda.hhs.gov. If you have any questions regarding this letter, please contact, Ms. Gina Eng, Compliance Officer, at (240) 753-3935 or via email at Gina.Eng@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRamon A. Hernandez\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast IV Division","Mena Food Group, LLC","mena-food-group-llc-673814-08082024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmena-food-group-llc-673814-08082024","2026-10-26T08:09:23.862154+00:00","2024-12-03","673814","Food & Beverages","Mr. David Mena","2026-08-19T17:57:41.238+00:00","Electronic Mail","24-HAFE4-WL-04","2024-08-08",{"id":78,"raw":79,"subject":84,"body_html":85,"body_text":86,"firm_name":87,"letter_id":88,"created_at":89,"fei_number":20,"letter_url":90,"updated_at":91,"action_type":23,"case_status":24,"posted_date":92,"marcs_cms_no":93,"product_type":71,"closeout_date":20,"issuing_office":83,"recipient_name":94,"body_fetched_at":95,"delivery_method":96,"recipient_title":20,"reference_number":20,"action_taken_date":97,"medical_device_id":20,"response_letter_date":20},97,[80,81,82,83,84,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fys-group-inc-731129-06082026\">YS Group Inc.\u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yamato Miura, Co-Chief Executive Officer and Chief Financial Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Steve Tieu, Co-Chief Executive Officer and Secretary \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>YS Group Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1108 S Baldwin Ave Suite B6\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Arcadia\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91007\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS #731129\u003C\u002Fp>\u003Cp>Dear Mr. Miura and Mr. Tieu:\u003C\u002Fp>\u003Cp>On April 30, 2026 through May 12, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of YS Group Inc. located at 1108 S Baldwin Ave Suite B6, Arcadia, CA 91007. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import.\u003C\u002Fp>\u003Cp>Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response dated June 2, 2026 in which you stated you developed the hazard analysis for the tofu skin imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and requested \u003Cstrong>(b)(4)\u003C\u002Fstrong> to provide a certificate of analysis for future shipments of tofu skin as documentation of your verification activity. You also clarified that the foreign supplier of the buckwheat flour listed on the Form FDA 483a was a distributor and you will update your database to the correct manufacturer. You included the hazard analysis for tofu skin imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the response. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Tofu Skin imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Dried Seaweed imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Buckwheat Flour imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During our inspection you provided the following:\u003C\u002Fp>\u003Cul>\u003Cli>Supplier HACCP Verification Records for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>HACCP plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You stated that you are not familiar with FSVP requirements and have just recently started to conduct and document FSVP activities. However, it is not clear how these documents would apply to your FSVP program as the HACCP records are for fish and fishery products, and you did not explain how they would apply to your FSVP program.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the food from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Lydia Chan, Compliance Officer, 1201 Harbor Bay Parkway, Alameda, CA 94502. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Lydia Chan via email at lydia.chan@fda.hhs.gov. Please reference CMS #731129 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dr. Kathleen Turner\u003Cbr>Program Division Director\u003Cbr>Division of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nYamato Miura, Co-Chief Executive Officer and Chief Financial Officer\n\nRecipient Title\n\nSteve Tieu, Co-Chief Executive Officer and Secretary\n\nYS Group Inc.\n\n1108 S Baldwin Ave Suite B6\n\nArcadia, CA 91007\n\nUnited States\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nRe: CMS #731129\nDear Mr. Miura and Mr. Tieu:\nOn April 30, 2026 through May 12, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of YS Group Inc. located at 1108 S Baldwin Ave Suite B6, Arcadia, CA 91007. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import.\nBecause of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response dated June 2, 2026 in which you stated you developed the hazard analysis for the tofu skin imported from (b)(4) and requested (b)(4) to provide a certificate of analysis for future shipments of tofu skin as documentation of your verification activity. You also clarified that the foreign supplier of the buckwheat flour listed on the Form FDA 483a was a distributor and you will update your database to the correct manufacturer. You included the hazard analysis for tofu skin imported from (b)(4) with the response. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\nTofu Skin imported from (b)(4)\nDried Seaweed imported from (b)(4)\nBuckwheat Flour imported from (b)(4)\nDuring our inspection you provided the following:\nSupplier HACCP Verification Records for (b)(4), and (b)(4)\nHACCP plan for (b)(4)\nYou stated that you are not familiar with FSVP requirements and have just recently started to conduct and document FSVP activities. However, it is not clear how these documents would apply to your FSVP program as the HACCP records are for fish and fishery products, and you did not explain how they would apply to your FSVP program.\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the food from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Lydia Chan, Compliance Officer, 1201 Harbor Bay Parkway, Alameda, CA 94502. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Lydia Chan via email at lydia.chan@fda.hhs.gov. Please reference CMS #731129 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nDr. Kathleen Turner\nProgram Division Director\nDivision of West Coast Imports","YS Group Inc.","ys-group-inc-731129-06082026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fys-group-inc-731129-06082026","2026-10-26T08:10:37.57101+00:00","2026-06-16","731129","Yamato Miura, Co-Chief Executive Officer and Chief Financial Officer","2026-08-19T04:37:08.527+00:00","Via Express Delivery","2026-06-08",{"id":99,"raw":100,"subject":84,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":89,"fei_number":20,"letter_url":108,"updated_at":109,"action_type":23,"case_status":24,"posted_date":110,"marcs_cms_no":111,"product_type":71,"closeout_date":20,"issuing_office":83,"recipient_name":112,"body_fetched_at":113,"delivery_method":114,"recipient_title":20,"reference_number":20,"action_taken_date":115,"medical_device_id":20,"response_letter_date":20},359,[101,102,103,83,84,13,13,13],"\u003Ctime datetime=\"2026-01-27T05:00:00Z\">01\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-23T04:00:00Z\">10\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmg-group-usa-718152-10232025\">MG GROUP USA\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nunziata Di Nardo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MG GROUP USA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>87 2nd St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Harrison\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10528-4411\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 23, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>RE: CMS# 718152\u003C\u002Fp>\u003Cp>Dear Ms. Nunziata Di Nardo:\u003C\u002Fp>\u003Cp>On August 14, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of MG GROUP USA, located at 87 2nd St Harrison, NY 10528-4411We also conducted an inspection between February 8, 2023 through February 21, 2023 and September 9, 2024 through September16, 2024. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. Despite providing a response to the 483a, you did not provide any documentation to show proof that you \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that you have developed FSVP’s for any of the foods you import.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>White Truffle Olive Oil from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Fresh Summer Truffles from foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Fresh Black Truffles from foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Spiridoula Dimopoulos, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Spiridoul.Dimopoulos@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Dimopoulos via email at Spiridoul.Dimopoulos@fda.hhs.gov. Please reference CMS # 718152 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Joseph S. Tomao\u003Cbr>Program Division Director\u003Cbr>Division of Northeast Import\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nNunziata Di Nardo\n\nRecipient Title\n\nOwner\n\nMG GROUP USA\n\n87 2nd St\n\nHarrison, NY 10528-4411\n\nUnited States\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nOctober 23, 2025\nWARNING LETTER\nRE: CMS# 718152\nDear Ms. Nunziata Di Nardo:\nOn August 14, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of MG GROUP USA, located at 87 2nd St Harrison, NY 10528-4411We also conducted an inspection between February 8, 2023 through February 21, 2023 and September 9, 2024 through September16, 2024. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. Despite providing a response to the 483a, you did not provide any documentation to show proof that you (b)(4) and that you have developed FSVP’s for any of the foods you import.\nYour significant violations of the FSVP regulation are as follows:\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including the following foods:\nWhite Truffle Olive Oil from (b)(4) located in (b)(4)\nFresh Summer Truffles from foreign supplier (b)(4) located in (b)(4)\nFresh Black Truffles from foreign supplier (b)(4) located in (b)(4)\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Spiridoula Dimopoulos, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Spiridoul.Dimopoulos@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Dimopoulos via email at Spiridoul.Dimopoulos@fda.hhs.gov. Please reference CMS # 718152 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nCDR Joseph S. Tomao\nProgram Division Director\nDivision of Northeast Import","MG GROUP USA","mg-group-usa-718152-10232025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmg-group-usa-718152-10232025","2026-10-26T08:09:24.471695+00:00","2026-01-27","718152","Nunziata Di Nardo","2026-08-19T07:16:54.962+00:00","Via Email","2025-10-23",{"id":117,"raw":118,"subject":123,"body_html":124,"body_text":125,"firm_name":126,"letter_id":127,"created_at":128,"fei_number":20,"letter_url":129,"updated_at":130,"action_type":23,"case_status":24,"posted_date":131,"marcs_cms_no":132,"product_type":133,"closeout_date":20,"issuing_office":134,"recipient_name":135,"body_fetched_at":136,"delivery_method":137,"recipient_title":20,"reference_number":20,"action_taken_date":138,"medical_device_id":20,"response_letter_date":20},2165,[119,120,121,122,123,13,13,13],"\u003Ctime datetime=\"2023-03-14T13:20:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-19T05:00:00Z\">01\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fb-j-group-641099-01192023\">B &amp; J Group\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Tilghman B. Frey\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>B &amp; J Group\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1001 New Ford Mill Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morrisville\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19067\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 641099\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 19, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Frey:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). FDA has reviewed the records you submitted in response to our January 25, 2022 and February 9, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 374(a)(4)) for your facility, B &amp; J Group, FEI 3010096700, at 1001 New Ford Mill Road, Morrisville, Pennsylvania.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs as described in your response to our 704(a)(4) request do not conform to CGMP regulations, your drug products are deemed adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B))\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>704(a)(4) Request for Records and Related CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and (b))\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your response to our request for records and other information under section 704(a)(4) indicated that you are a contract filler of OTC hand sanitizer drug products and that you did not test the finished drug products before release. Specifically, in response to our request to provide the finished product specifications and test methods for both analytical and microbiological tests for each hand sanitizer product manufactured for distribution in the United States, you stated that this is “Done by customer” and “We just filled the bottles.”\u003C\u002Fp>\n\n\u003Cp>Owners and contract manufacturing facilities are both responsible for CGMPs, which includes the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.\u003C\u002Fp>\n\n\u003Cp>Full release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision:\u003Cbr>\n&nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; o A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not demonstrate adequate testing of the identity of incoming components used in the manufacture of your drug products. Specifically, your response stated that raw material identity testing for each lot of each component is “Not Applicable,” testing of ethanol or isopropyl alcohol and methanol is “Done by each customer,” and testing the potency (assay) of ethanol or isopropyl alcohol used for hand sanitizer is “Not Applicable.”\u003C\u002Fp>\n\n\u003Cp>You manufacture multiple drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19)\u003C\u002Fem> at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the information you provided, you did not demonstrate that your manufacturing processes are reproducible and controlled to yield a product of uniform character and quality. For example, we asked you to provide a copy of the most recent, completed batch production record for each hand sanitizer product manufactured. You stated in your response that batch production records are “Maintained by customers.”\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products distributed by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov and CDER-OC-OMQ-Communications@fda.hhs.gov. Please also identify your response with FEI 3010096700.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u002F District Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOPQO Division I \u002F New Jersey District\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the&nbsp;guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because B &amp; J Group hand sanitizer drug products were not prepared under the circumstances described in this guidance, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Tilghman B. Frey\n\nRecipient Title\n\nChief Operating Officer\n\nB & J Group\n\n1001 New Ford Mill Rd.\n\nMorrisville, PA 19067\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter 641099\n\nJanuary 19, 2023\n\nDear Mr. Frey:\n\nYour facility is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). FDA has reviewed the records you submitted in response to our January 25, 2022 and February 9, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 374(a)(4)) for your facility, B & J Group, FEI 3010096700, at 1001 New Ford Mill Road, Morrisville, Pennsylvania.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs as described in your response to our 704(a)(4) request do not conform to CGMP regulations, your drug products are deemed adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B))1.\n\n704(a)(4) Request for Records and Related CGMP Violations\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and (b))\n\nYour response to our request for records and other information under section 704(a)(4) indicated that you are a contract filler of OTC hand sanitizer drug products and that you did not test the finished drug products before release. Specifically, in response to our request to provide the finished product specifications and test methods for both analytical and microbiological tests for each hand sanitizer product manufactured for distribution in the United States, you stated that this is “Done by customer” and “We just filled the bottles.”\n\nOwners and contract manufacturing facilities are both responsible for CGMPs, which includes the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.\n\nFull release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\nIn response to this letter, provide:\n\n• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision:\n\no An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nBased on the records and information you provided, you did not demonstrate adequate testing of the identity of incoming components used in the manufacture of your drug products. Specifically, your response stated that raw material identity testing for each lot of each component is “Not Applicable,” testing of ethanol or isopropyl alcohol and methanol is “Done by each customer,” and testing the potency (assay) of ethanol or isopropyl alcohol used for hand sanitizer is “Not Applicable.”\n\nYou manufacture multiple drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nBased on the information you provided, you did not demonstrate that your manufacturing processes are reproducible and controlled to yield a product of uniform character and quality. For example, we asked you to provide a copy of the most recent, completed batch production record for each hand sanitizer product manufactured. You stated in your response that batch production records are “Maintained by customers.”\n\nIn response to this letter, provide:\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n• A list of all batches of any hand sanitizer drug products distributed by your firm, and a full reconciliation of all material you distributed.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov and CDER-OC-OMQ-Communications@fda.hhs.gov. Please also identify your response with FEI 3010096700.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\u002F District Director\n\nU.S. Food and Drug Administration\n\nOPQO Division I \u002F New Jersey District\n\n________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because B & J Group hand sanitizer drug products were not prepared under the circumstances described in this guidance, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.","B & J Group","b-j-group-641099-01192023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fb-j-group-641099-01192023","2026-10-26T08:08:00.033895+00:00","2023-03-14","641099","Drugs","Division of Pharmaceutical Quality Operations I","Mr. Tilghman B. Frey","2026-08-20T01:12:01.995+00:00","VIA UPS and Electronic Mail","2023-01-19",{"id":140,"raw":141,"subject":147,"body_html":148,"body_text":149,"firm_name":150,"letter_id":151,"created_at":45,"fei_number":20,"letter_url":152,"updated_at":153,"action_type":23,"case_status":24,"posted_date":154,"marcs_cms_no":155,"product_type":133,"closeout_date":20,"issuing_office":145,"recipient_name":156,"body_fetched_at":157,"delivery_method":158,"recipient_title":20,"reference_number":20,"action_taken_date":159,"medical_device_id":20,"response_letter_date":20},3217,[142,143,144,145,146,13,13,13],"\u003Ctime datetime=\"2021-08-10T13:20:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-04T04:00:00Z\">08\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbbc-group-limited-614659-08042021\">BBC Group Limited\u003C\u002Fa>","Center for Drug Evaluation and Research","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Alan Wong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BBC Group Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Yangxia Development Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pumei Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yunxiao County\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>363300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-21-53\u003C\u002Fp>\n\n\u003Cp>August 4, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Wong,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, BBC Group Limited, FEI 3010165327, at Yangxia Development Zone, Pumei Town, Yunxiao County, Zhangzhou, China, from March 22 to March 26, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, your firm manufactures L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products that are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 13, 2021 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) drug products, including alcohol-based hand sanitizers\u003Csup>\u003Cem>\u003Cstrong>[1]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. During the inspection of your facility, our investigator attempted to review analytical data from your gas chromatograph (GC) supporting the release of drug products distributed to the United States. However, your firm stated that all testing data from 2018 to 2020 was lost approximately one month prior to the initiation of our inspection. The GC is used to analyze the identity and strength of active ingredients and impurities contained in your OTC drug products, as well as other critical parameters. According to firm management, the data is unrecoverable. While your firm retained a static copy of laboratory records for review (i.e., paper record), they were inadequate as they did not preserve the dynamic record format of the full chromatographs to support test results and they did not include system suitability documentation that are part of the complete, original record.\u003C\u002Fp>\n\n\u003Cp>Additionally, our investigator observed that the computerized system and software associated with your GC lacked restricted access. For example, your laboratory employees who used the GC to perform analyses of drug products all logged in as “System Administrator,” which does not require a password, and had full system administration rights. In addition, audit trails on your GC were not enabled.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you did not retain all original, dynamic records, obtained during the course of testing on other laboratory equipment. Your viscometer and UV-Vis spectrophotometer had the capability to save data from product\u002Fmaterial testing. Despite having this capability, your analysts failed to save the complete, dynamic testing data, and therefore the data was not available for review by the FDA investigator. The viscometer is used to measure the viscosity of finished drug products during release testing and the UV-Vis spectrophotometer is used to measure ethanol content during raw material testing.\u003C\u002Fp>\n\n\u003Cp>Your firm also utilizes electronic spreadsheets to input data for your stability program. However, these spreadsheets are not controlled and there is no protection to prevent data manipulation, overwriting, or erasure.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that you purchased and\u002For installed additional equipment to address this violation, including, but not limited to, an uninterrupted power source, remote hard drive, electrical equipment, and new software. Your response also states that you have updated and developed associated procedures, created individual accounts for all personnel that utilize laboratory equipment, and conducted accompanying trainings. However, your response is inadequate because it lacked supporting documentation, including evidence to support that the computer security controls were effective at preventing data and document manipulation. Additionally, you did not perform a retrospective risk assessment into how system vulnerabilities may have impacted data integrity.\u003C\u002Fp>\n\n\u003Cp>Your firm does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003Cbr>\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed Corrective Action and Preventive Action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003Cbr>\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory computer systems. This should include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A list of all hardware that includes all equipment, both standalone and network, in your laboratory.\u003Cbr>\n&nbsp; &nbsp; o Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\u003Cbr>\n&nbsp; &nbsp; o A list of all software configurations and versions, details of all user privileges, and oversight responsibilities for each of your laboratory systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory computer systems, and their organizational affiliations and titles. Also describe how you will ensure laboratory staff are not given administrative rights, or other permissions that compromise data retention or reliability.\u003Cbr>\n&nbsp; &nbsp; o System security provisions, including, but not limited to, whether unique user names\u002Fpasswords are always used, and their confidentiality safeguarded.\u003Cbr>\n&nbsp; &nbsp; o Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\u003Cbr>\n&nbsp; &nbsp; o Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\u003Cbr>\n&nbsp; &nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, appropriate user role assignments, secondary review of all analyses, and other system controls.\u003Cbr>\n&nbsp; &nbsp; o Provisions for oversight by QA managers, executives, and internal auditors with appropriate information technology (IT) expertise (e.g., to evaluate infrastructure, configuration, network requirements, data management practices, and segregation of duties including administrator rights).\u003Cbr>\n&nbsp; &nbsp; o A remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Include a full CAPA plan and any improvements made to date.\u003Cbr>\n&nbsp; &nbsp; o An independent, thorough retrospective assessment into the impact of laboratory system design, control, and staff practices on your data accuracy, completeness, and retention since January 1, 2018.\u003Cbr>\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your analytical test methods were not adequately validated, including those for the active ingredient ethanol, which is used to manufacture your alcohol-based hand sanitizers, and analysis for the impurity \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Specifically, no system suitability requirements were present and reference standards were not identified. Data must be available to establish that the analytical procedures used in testing meet proper standards of accuracy, sensitivity, specificity, and reproducibility and are suitable for their intended purpose.\u003Cbr>\n\u003Cbr>\nIn your response, you indicated that you updated test methods, established method validation protocols, and completed test method evaluation. However, your response is inadequate for the following reasons.\u003Cbr>\n• The response lacked information on the analyte reference standards used for the method validation.\u003Cbr>\n• The response lacked method validation details on identity of the tested analytes, system suitability, method specificity data, preparations of the analyte stock solutions, and accuracy and precision data from spike and recovery experiments at different concentration levels.\u003Cbr>\n• The response lacked an assessment of drug products manufactured utilizing the deficient methods.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003Cbr>\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• An independent assessment of all test methods and data review procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and validation to determine whether they are fit for intended purposes.\u003Cbr>\n• Your test results, using an adequately validated test method, of retains for all finished drug products, within expiry. You should test all appropriate quality attributes of each batch that you distributed into U.S. commerce to ensure that your drug products conform to appropriate standards of identity, strength, quality, and purity. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Analytical Procedures and Methods Validation for Drugs and Biologics\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of method validation at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our inspection, the investigator observed rust on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and product contact surfaces of four of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to manufacture drug products, including the manufacture of your OTC hand sanitizers. Upon request, you provided our investigator with manufacturing equipment maintenance logs for the aforementioned \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These documents were only available in Chinese. After the conclusion of the inspection, the FDA had the document translated and found that the document provided was for equipment identified as “liquid washing pan” with serial number WJB-001, which is located in Workshop \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> floor, and not the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with equipment ID’s 12 through 15 located in Workshop \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> floor that were observed with rust. FDA is concerned that you provided maintence records for different equipment than those requested during the inspection.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that you replaced all the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response failed to address the rust documented in other parts of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, your response is inadequate as you failed to revise your cleaning and maintenance procedures to prevent recurrence of this issue, you failed to perform a risk assessment of drug products manufactured in the four \u003Cstrong>(b)(4)\u003C\u002Fstrong> that contained rust, and you did not determine the root cause of why employees who perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspections of manufacturing equipment did not observe the rust in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003Cbr>\n• Your plan for continued manufacture of drug products in the aforementioned \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing rust. Our inspection observed rust on and around the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and other parts of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n• A risk assessment for drug products manufactured in the four \u003Cstrong>(b)(4)\u003C\u002Fstrong> that contained rust to determine if a market action is warranted.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“HAND SANTIZER. . .\u003Cstrong>Drug Facts\u003C\u002Fstrong>. . .\u003Cstrong>Uses\u003C\u002Fstrong>. . . to decrease bacteria on the skin that could cause disease. . . \u003Cstrong>Direction\u003C\u002Fstrong> – rub a dime sized drop into hands.”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under Section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exemptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER drug products are GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products have been the subject of rulemaking under FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use in a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act, addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products contain the active ingredient “chloroxylenol 0.015%.” Chloroxylenol is not permitted as an active ingredient for use as a consumer antiseptic hand rub drug product under the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>[2]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such products do not conform with the TFM, nor are they consistent with the formulations described in FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>[3]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, CHERRY) SCENTED HAND SANITIZER products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Disparities in Records Submitted to the Agency\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 30, 2020 as information you provided in your response to a FDA request for records pursuant to section 704(a)(4) of the FD&amp;C Act, 21 U.S.C. 374(a)(4), did not appear to conform to CGMP. Specifically, your response to the FDA records request demonstrated a lack of analytical data supporting drug product release, as required under 21 CFR 211.165. Subsequent to your placement on Import Alert, you submitted additional data to the agency, now including test results of drug products you distributed to the United States. To evaluate the disparity in the records provided, and in part to evaluate if your firm should be removed from import alert, FDA conducted an inspection of your facility. However, upon physical inspection of your facility, the raw data related to your submitted test results were unavailable. The records you submitted electronically prior to the inspection were not consistent with what was observed during the FDA inspection of your facility. Your firm will remain on import alert until FDA is satisfied that the appearance of violations observed have been resolved.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 23, 2020.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP.We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at BBC Group Limited, FEI 3010165327, at Yangxia Development Zone; Pumei Town, Yunxiao County; Zhangzhou, China into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3010165327 and ATTN: CDR Frank Verni.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCC:\u003Cbr>\nMr. Richard Pecora, Consultant\u003Cbr>\nPecora Consulting LLC\u003Cbr>\n51 Sunnywood Drive\u003Cbr>\nWestfield, NJ 07090\u003Cbr>\npecoraconsulting@verizon.net\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Are view of the purported formulations on the drug product’s labeling indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic handwashes and healthcare personnel handwashes an alcohol concentration of 60 to 95% by volume in an aqueous solution denatured in accordance with Bureau of Alcohol, Tobacco and Firearms regulations. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Alan Wong\n\nRecipient Title\n\nGeneral Manager\n\nBBC Group Limited\n\nYangxia Development Zone\n\nPumei Town\n\nYunxiao County\n\n363300\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWarning Letter 320-21-53\n\nAugust 4, 2021\n\nDear Mr. Wong,\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, BBC Group Limited, FEI 3010165327, at Yangxia Development Zone, Pumei Town, Yunxiao County, Zhangzhou, China, from March 22 to March 26, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, your firm manufactures L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products that are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your April 13, 2021 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\nCGMP Violations\n\n1. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nYour firm manufactures over-the-counter (OTC) drug products, including alcohol-based hand sanitizers[1]. During the inspection of your facility, our investigator attempted to review analytical data from your gas chromatograph (GC) supporting the release of drug products distributed to the United States. However, your firm stated that all testing data from 2018 to 2020 was lost approximately one month prior to the initiation of our inspection. The GC is used to analyze the identity and strength of active ingredients and impurities contained in your OTC drug products, as well as other critical parameters. According to firm management, the data is unrecoverable. While your firm retained a static copy of laboratory records for review (i.e., paper record), they were inadequate as they did not preserve the dynamic record format of the full chromatographs to support test results and they did not include system suitability documentation that are part of the complete, original record.\n\nAdditionally, our investigator observed that the computerized system and software associated with your GC lacked restricted access. For example, your laboratory employees who used the GC to perform analyses of drug products all logged in as “System Administrator,” which does not require a password, and had full system administration rights. In addition, audit trails on your GC were not enabled.\n\nFurthermore, you did not retain all original, dynamic records, obtained during the course of testing on other laboratory equipment. Your viscometer and UV-Vis spectrophotometer had the capability to save data from product\u002Fmaterial testing. Despite having this capability, your analysts failed to save the complete, dynamic testing data, and therefore the data was not available for review by the FDA investigator. The viscometer is used to measure the viscosity of finished drug products during release testing and the UV-Vis spectrophotometer is used to measure ethanol content during raw material testing.\n\nYour firm also utilizes electronic spreadsheets to input data for your stability program. However, these spreadsheets are not controlled and there is no protection to prevent data manipulation, overwriting, or erasure.\n\nIn your response, you indicated that you purchased and\u002For installed additional equipment to address this violation, including, but not limited to, an uninterrupted power source, remote hard drive, electrical equipment, and new software. Your response also states that you have updated and developed associated procedures, created individual accounts for all personnel that utilize laboratory equipment, and conducted accompanying trainings. However, your response is inadequate because it lacked supporting documentation, including evidence to support that the computer security controls were effective at preventing data and document manipulation. Additionally, you did not perform a retrospective risk assessment into how system vulnerabilities may have impacted data integrity.\n\nYour firm does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\n\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\n\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed Corrective Action and Preventive Action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory computer systems. This should include, but not be limited to:\n\no A list of all hardware that includes all equipment, both standalone and network, in your laboratory.\n\no Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\n\no A list of all software configurations and versions, details of all user privileges, and oversight responsibilities for each of your laboratory systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory computer systems, and their organizational affiliations and titles. Also describe how you will ensure laboratory staff are not given administrative rights, or other permissions that compromise data retention or reliability.\n\no System security provisions, including, but not limited to, whether unique user names\u002Fpasswords are always used, and their confidentiality safeguarded.\n\no Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\n\no Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\n\no A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, appropriate user role assignments, secondary review of all analyses, and other system controls.\n\no Provisions for oversight by QA managers, executives, and internal auditors with appropriate information technology (IT) expertise (e.g., to evaluate infrastructure, configuration, network requirements, data management practices, and segregation of duties including administrator rights).\n\no A remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Include a full CAPA plan and any improvements made to date.\n\no An independent, thorough retrospective assessment into the impact of laboratory system design, control, and staff practices on your data accuracy, completeness, and retention since January 1, 2018.\n\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYour analytical test methods were not adequately validated, including those for the active ingredient ethanol, which is used to manufacture your alcohol-based hand sanitizers, and analysis for the impurity (b)(4). Specifically, no system suitability requirements were present and reference standards were not identified. Data must be available to establish that the analytical procedures used in testing meet proper standards of accuracy, sensitivity, specificity, and reproducibility and are suitable for their intended purpose.\n\nIn your response, you indicated that you updated test methods, established method validation protocols, and completed test method evaluation. However, your response is inadequate for the following reasons.\n\n• The response lacked information on the analyte reference standards used for the method validation.\n\n• The response lacked method validation details on identity of the tested analytes, system suitability, method specificity data, preparations of the analyte stock solutions, and accuracy and precision data from spike and recovery experiments at different concentration levels.\n\n• The response lacked an assessment of drug products manufactured utilizing the deficient methods.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• An independent assessment of all test methods and data review procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and validation to determine whether they are fit for intended purposes.\n\n• Your test results, using an adequately validated test method, of retains for all finished drug products, within expiry. You should test all appropriate quality attributes of each batch that you distributed into U.S. commerce to ensure that your drug products conform to appropriate standards of identity, strength, quality, and purity. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\nSee FDA’s guidance document Analytical Procedures and Methods Validation for Drugs and Biologics for general principles and approaches that FDA considers appropriate elements of method validation at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload.\n\n3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nDuring our inspection, the investigator observed rust on (b)(4) and product contact surfaces of four of the (b)(4) used to manufacture drug products, including the manufacture of your OTC hand sanitizers. Upon request, you provided our investigator with manufacturing equipment maintenance logs for the aforementioned (b)(4). These documents were only available in Chinese. After the conclusion of the inspection, the FDA had the document translated and found that the document provided was for equipment identified as “liquid washing pan” with serial number WJB-001, which is located in Workshop (b)(4) on the (b)(4) floor, and not the (b)(4) with equipment ID’s 12 through 15 located in Workshop (b)(4) on the (b)(4) floor that were observed with rust. FDA is concerned that you provided maintence records for different equipment than those requested during the inspection.\n\nIn your response, you indicated that you replaced all the (b)(4) in your (b)(4). However, your response failed to address the rust documented in other parts of the (b)(4). Additionally, your response is inadequate as you failed to revise your cleaning and maintenance procedures to prevent recurrence of this issue, you failed to perform a risk assessment of drug products manufactured in the four (b)(4) that contained rust, and you did not determine the root cause of why employees who perform (b)(4) inspections of manufacturing equipment did not observe the rust in the (b)(4).\n\nIn response to this letter, provide the following:\n\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n• Your plan for continued manufacture of drug products in the aforementioned (b)(4) containing rust. Our inspection observed rust on and around the (b)(4) and other parts of the (b)(4).\n\n• A risk assessment for drug products manufactured in the four (b)(4) that contained rust to determine if a market action is warranted.\n\nUnapproved New Drug and Misbranding Violations\n\nL.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as a consumer topical antiseptic.\n\nExamples of claims observed on the L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“HAND SANTIZER. . .Drug Facts. . .Uses. . . to decrease bacteria on the skin that could cause disease. . . Direction – rub a dime sized drop into hands.”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under Section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exemptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER drug products are GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products have been the subject of rulemaking under FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use in a consumer antiseptic rub.\n\nSection 505G of the FD&C Act, addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products contain the active ingredient “chloroxylenol 0.015%.” Chloroxylenol is not permitted as an active ingredient for use as a consumer antiseptic hand rub drug product under the 1994 TFM.[2] Such products do not conform with the TFM, nor are they consistent with the formulations described in FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.[3]\n\nAdditionally, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, CHERRY) SCENTED HAND SANITIZER products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nDisparities in Records Submitted to the Agency\n\nFDA placed your firm on Import Alert 66-40 on September 30, 2020 as information you provided in your response to a FDA request for records pursuant to section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4), did not appear to conform to CGMP. Specifically, your response to the FDA records request demonstrated a lack of analytical data supporting drug product release, as required under 21 CFR 211.165. Subsequent to your placement on Import Alert, you submitted additional data to the agency, now including test results of drug products you distributed to the United States. To evaluate the disparity in the records provided, and in part to evaluate if your firm should be removed from import alert, FDA conducted an inspection of your facility. However, upon physical inspection of your facility, the raw data related to your submitted test results were unavailable. The records you submitted electronically prior to the inspection were not consistent with what was observed during the FDA inspection of your facility. Your firm will remain on import alert until FDA is satisfied that the appearance of violations observed have been resolved.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on September 23, 2020.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP.We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at BBC Group Limited, FEI 3010165327, at Yangxia Development Zone; Pumei Town, Yunxiao County; Zhangzhou, China into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3010165327 and ATTN: CDR Frank Verni.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nMr. Richard Pecora, Consultant\n\nPecora Consulting LLC\n\n51 Sunnywood Drive\n\nWestfield, NJ 07090\n\npecoraconsulting@verizon.net\n\n________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Are view of the purported formulations on the drug product’s labeling indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic handwashes and healthcare personnel handwashes an alcohol concentration of 60 to 95% by volume in an aqueous solution denatured in accordance with Bureau of Alcohol, Tobacco and Firearms regulations. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n3 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","BBC Group Limited","bbc-group-limited-614659-08042021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbbc-group-limited-614659-08042021","2026-10-26T08:08:01.938176+00:00","2021-08-10","614659","Mr. Alan Wong","2026-08-20T02:42:31.43+00:00","VIA UPS","2021-08-04",{"id":161,"raw":162,"subject":168,"body_html":169,"body_text":170,"firm_name":171,"letter_id":172,"created_at":66,"fei_number":20,"letter_url":173,"updated_at":174,"action_type":23,"case_status":24,"posted_date":175,"marcs_cms_no":176,"product_type":71,"closeout_date":20,"issuing_office":166,"recipient_name":177,"body_fetched_at":178,"delivery_method":96,"recipient_title":20,"reference_number":20,"action_taken_date":179,"medical_device_id":20,"response_letter_date":20},1456,[163,164,165,166,167,13,13,13],"\u003Ctime datetime=\"2024-05-14T13:20:00Z\">05\u002F14\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-17T04:00:00Z\">04\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgnr-group-co-ltd-679766-04172024\">G.N.R. Group Co., LTD.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Juice\u002FHACCP\u002FAdulterated\u003Cbr \u002F>\r\n","Juice\u002FHACCP\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ritz Chalermchaicharn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>G.N.R. Group Co., LTD.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>273 Rama 3 Soi 53, Rama 3 Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yan Nawa\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bangkok\u003C\u002Fspan> \u003Cspan>10120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thailand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@gnrgroup.co.th\"> info@gnrgroup.co.th\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 17, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nReference No. 679766\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chalermchaicharn:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your food manufacturing facility located at 273 Rama 3 Soi 53, Rama 3 Rd, Yan Nawa, Bangkok Thailand 10120 from January 22 to January 23, 2024. Your firm manufactures a frozen fruits, vegetables, and coconut juice. The inspection revealed serious deviations of the juice Hazard Analysis and Critical Control Point (HACCP) Systems regulation, Title 21, Code of Federal Regulations, Part 120 (21 CFR 120). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations, that lists the serious deviations found at your firm.\u003C\u002Fp>\n\n\u003Cp>In accordance with 21 CFR 120.9, failure of a processor to have and implement a HACCP system that complies with 21 CFR 120.6, 120.7, and 120.8, or otherwise to operate in accordance with the requirements of Part 120, renders the juice products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21U.S.C. § 342(a)(4). Accordingly, your juice products, which are subject to the requirements of 21 CFR Part 120 are adulterated in that they may have been prepared, packed, or held under conditions whereby it may have been rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>We received your email response to the FDA-483 on February 6, 2024, and address the details of your response below. Based on our review of the inspectional findings and the response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\n\n\u003Cp>Your significant violation is as follows:\u003Cbr>\n\u003Cbr>\nYou must include in your HACCP plan control measures that will consistently produce, at a minimum, a 5-log reduction, for a period at least as long as the shelf life of the product when stored under normal and moderate abuse conditions, in the pertinent microorganism, as required by 21 CFR 120.24(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your HACCP plan for Frozen Coconut Juice lists the critical limits for pasteurization of \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Celsius for \u003Cstrong>(b)(4)\u003C\u002Fstrong> seconds at two critical control points: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to control pathogenic bacteria. However, your Frozen Coconut Juice is a low-acid juice product, and \u003Cem>Clostridium botulinum\u003C\u002Fem> is the pertinent microorganism. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process for both the coconut meat and for the coconut water are not sufficient to produce a minimum 5-log reduction in non-proteolytic \u003Cem>Clostridium botulinum&nbsp;\u003C\u002Fem>(NPB), the pertinent microorganism. You have not provided documentation to demonstrate the identified control measures will consistently produce a 5-log reduction of the pertinent microorganisms in your Frozen Coconut Juice.\u003C\u002Fp>\n\n\u003Cp>In your response, you cited the article, “Thermal Pasteurization of RTE Foods and Vegetables,” as support for your critical limits for the pasteurization (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong> process). However, we note that the article recognizes, “… for low-acid juices such as carrot juice, C. botulinum may be present and produce toxins, and therefore becomes the pathogen hazard of concern”. The article further states, “A severe pasteurization process of F90°C = 10.0 min aiming at a 6D process inactivation of nonproteolytic C. botulinum allows a product shelf life of up to 6 weeks at 5°C”. We recommend you engage with a process authority to develop a thermal process that will consistently produce a minimum 5-log reduction in non-proteolytic \u003Cem>Clostridium botulinum&nbsp;\u003C\u002Fem>(NPB). In your response to this letter, you should provide data demonstrating the efficacy of the proposed thermal treatment for Frozen Coconut Juice you produce (i.e., the treatment will repeatedly and reliably produce the required microbial reduction).\u003C\u002Fp>\n\n\u003Cp>This letter may not list all the violations at your facility. You are responsible for ensuring that your facility operates in compliance with the Act and all applicable regulations. You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. If you do not believe your products are in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. Responding in English will help to assist us in our review of your documentation.\u003C\u002Fp>\n\n\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take action to refuse admission of your juice products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including subjecting it to detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the juice HACCP regulation is Import Alert #20-07. You may view this alert at: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_761.html.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Victoria Wagoner, Compliance Officer, Office of Compliance, Division of Enforcement, Food Assessment and Adulteration Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Victoria Wagoner via email at Victoria.Wagoner@fda.hhs.gov. Please reference 679766 on any submissions and within the subject line of any emails to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Ritz Chalermchaicharn\n\nRecipient Title\n\nGeneral Manager\n\nG.N.R. Group Co., LTD.\n\n273 Rama 3 Soi 53, Rama 3 Rd\n\nYan Nawa\n\nBangkok 10120\n\nThailand\n\ninfo@gnrgroup.co.th\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nApril 17, 2024\n\nWARNING LETTER\n\nReference No. 679766\n\nDear Mr. Chalermchaicharn:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your food manufacturing facility located at 273 Rama 3 Soi 53, Rama 3 Rd, Yan Nawa, Bangkok Thailand 10120 from January 22 to January 23, 2024. Your firm manufactures a frozen fruits, vegetables, and coconut juice. The inspection revealed serious deviations of the juice Hazard Analysis and Critical Control Point (HACCP) Systems regulation, Title 21, Code of Federal Regulations, Part 120 (21 CFR 120). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations, that lists the serious deviations found at your firm.\n\nIn accordance with 21 CFR 120.9, failure of a processor to have and implement a HACCP system that complies with 21 CFR 120.6, 120.7, and 120.8, or otherwise to operate in accordance with the requirements of Part 120, renders the juice products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21U.S.C. § 342(a)(4). Accordingly, your juice products, which are subject to the requirements of 21 CFR Part 120 are adulterated in that they may have been prepared, packed, or held under conditions whereby it may have been rendered injurious to health.\n\nWe received your email response to the FDA-483 on February 6, 2024, and address the details of your response below. Based on our review of the inspectional findings and the response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\n\nYour significant violation is as follows:\n\nYou must include in your HACCP plan control measures that will consistently produce, at a minimum, a 5-log reduction, for a period at least as long as the shelf life of the product when stored under normal and moderate abuse conditions, in the pertinent microorganism, as required by 21 CFR 120.24(a).\n\nSpecifically, your HACCP plan for Frozen Coconut Juice lists the critical limits for pasteurization of (b)(4) degrees Celsius for (b)(4) seconds at two critical control points: “(b)(4)” and “(b)(4)” to control pathogenic bacteria. However, your Frozen Coconut Juice is a low-acid juice product, and Clostridium botulinum is the pertinent microorganism. Your (b)(4) process for both the coconut meat and for the coconut water are not sufficient to produce a minimum 5-log reduction in non-proteolytic Clostridium botulinum (NPB), the pertinent microorganism. You have not provided documentation to demonstrate the identified control measures will consistently produce a 5-log reduction of the pertinent microorganisms in your Frozen Coconut Juice.\n\nIn your response, you cited the article, “Thermal Pasteurization of RTE Foods and Vegetables,” as support for your critical limits for the pasteurization (i.e., (b)(4) process). However, we note that the article recognizes, “… for low-acid juices such as carrot juice, C. botulinum may be present and produce toxins, and therefore becomes the pathogen hazard of concern”. The article further states, “A severe pasteurization process of F90°C = 10.0 min aiming at a 6D process inactivation of nonproteolytic C. botulinum allows a product shelf life of up to 6 weeks at 5°C”. We recommend you engage with a process authority to develop a thermal process that will consistently produce a minimum 5-log reduction in non-proteolytic Clostridium botulinum (NPB). In your response to this letter, you should provide data demonstrating the efficacy of the proposed thermal treatment for Frozen Coconut Juice you produce (i.e., the treatment will repeatedly and reliably produce the required microbial reduction).\n\nThis letter may not list all the violations at your facility. You are responsible for ensuring that your facility operates in compliance with the Act and all applicable regulations. You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. If you do not believe your products are in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. Responding in English will help to assist us in our review of your documentation.\n\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take action to refuse admission of your juice products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including subjecting it to detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the juice HACCP regulation is Import Alert #20-07. You may view this alert at: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_761.html.\n\nPlease send your reply to the Food and Drug Administration, Attention: Victoria Wagoner, Compliance Officer, Office of Compliance, Division of Enforcement, Food Assessment and Adulteration Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Victoria Wagoner via email at Victoria.Wagoner@fda.hhs.gov. Please reference 679766 on any submissions and within the subject line of any emails to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition","G.N.R. Group Co., LTD.","gnr-group-co-ltd-679766-04172024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgnr-group-co-ltd-679766-04172024","2026-10-26T08:08:47.316352+00:00","2024-05-14","679766","Mr. Ritz Chalermchaicharn","2026-08-20T00:05:33.548+00:00","2024-04-17",{"id":181,"raw":182,"subject":186,"body_html":187,"body_text":188,"firm_name":189,"letter_id":190,"created_at":191,"fei_number":20,"letter_url":192,"updated_at":193,"action_type":23,"case_status":24,"posted_date":194,"marcs_cms_no":195,"product_type":71,"closeout_date":20,"issuing_office":166,"recipient_name":196,"body_fetched_at":197,"delivery_method":198,"recipient_title":20,"reference_number":20,"action_taken_date":199,"medical_device_id":20,"response_letter_date":20},3520,[183,184,185,166,186,13,13,13],"\u003Ctime datetime=\"2021-02-19T17:00:00Z\">02\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-18T05:00:00Z\">02\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsana-group-llc-612256-02182021\">SANA Group LLC\u003C\u002Fa>","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason W. Harris\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SANA Group LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1200 E. Woodhurst S-200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Springfield\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>65804\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>RE: [CMS:612256]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear Mr. Harris,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.sleepsana.com\u003Cspan>, \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>in December 2020 and has determined that you take orders there for your Sleep Sana “Sleep Drops” and “Sleep Shots” products. The claims on your website establish that your \u003Cspan>products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">\u003Cspan>\u003Cspan>www.fda.gov\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Examples of some of the\u003C\u002Fspan> \u003Cspan>website claims that provide evidence that your “Sleep Drops” and “Sleep Shots” are intended for use as drugs include:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>On the webpage for Sleep Sana “Sleep Drops” and “Sleep Shots” ingredients: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"GABA (an ingredient in your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan>\u003Cspan> is taken by mouth for relieving anxiety, ... and treating attention deficit hyperactivity disorder (ADHD). It is also used for ... stabilizing blood pressure, and relieving pain.\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"L-tryptophan (an ingredient in your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan>\u003Cspan> is used for insomnia, sleep apnea, depression, anxiety, facial pain, a severe form of premenstrual syndrome called premenstrual dysphoric disorder (PMDD), ... attention deficit-hyperactivity disorder (ADHD), Tourette's syndrome....\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>&nbsp;\"Valerian (an ingredient in your \u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan> is most commonly used for sleep disorders, especially the inability to sleep (insomnia).\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\"[Y]our body may produce melatonin (an ingredient in your \u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan> either earlier or later in the day than usual. This change can lead to symptoms of seasonal affective disorder (SAD), or winter depression.\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your “Sleep Drops” and “Sleep Shots” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. \u003Cspan>§§ \u003C\u002Fspan>331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. \u003Cspan>§ \u003C\u002Fspan>201.5).&nbsp; Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your “Sleep Drops” and “Sleep Shots” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for their intended purposes. Accordingly, your “Sleep Drops” and “Sleep Shots” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. \u003Cspan>§\u003C\u002Fspan> 331(a)]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take prompt action to address the violates cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations.&nbsp; Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.&nbsp; If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. Your reply should be sent via e-mail to \u003C\u002Fspan>\u003Ca href=\"mailto:FDAAdvisory@fda.hhs.gov\">\u003Cspan>FDAAdvisory@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>William A. Correll Jr.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Center for Food Safety and Applied Nutrition\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJason W. Harris\n\nRecipient Title\n\nOwner\n\nSANA Group LLC\n\n1200 E. Woodhurst S-200\n\nSpringfield, MO 65804\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nRE: [CMS:612256]\n\nDear Mr. Harris,\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.sleepsana.com, in December 2020 and has determined that you take orders there for your Sleep Sana “Sleep Drops” and “Sleep Shots” products. The claims on your website establish that your products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your “Sleep Drops” and “Sleep Shots” are intended for use as drugs include:\n\nOn the webpage for Sleep Sana “Sleep Drops” and “Sleep Shots” ingredients:\n\n\"GABA (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is taken by mouth for relieving anxiety, ... and treating attention deficit hyperactivity disorder (ADHD). It is also used for ... stabilizing blood pressure, and relieving pain.\"\n\n\"L-tryptophan (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is used for insomnia, sleep apnea, depression, anxiety, facial pain, a severe form of premenstrual syndrome called premenstrual dysphoric disorder (PMDD), ... attention deficit-hyperactivity disorder (ADHD), Tourette's syndrome....\"\n\n\"Valerian (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is most commonly used for sleep disorders, especially the inability to sleep (insomnia).\"\n\n\"[Y]our body may produce melatonin (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) either earlier or later in the day than usual. This change can lead to symptoms of seasonal affective disorder (SAD), or winter depression.\"\n\nYour “Sleep Drops” and “Sleep Shots” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Sleep Drops” and “Sleep Shots” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for their intended purposes. Accordingly, your “Sleep Drops” and “Sleep Shots” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address the violates cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. Your reply should be sent via e-mail to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam A. Correll Jr.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration","SANA Group LLC","sana-group-llc-612256-02182021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsana-group-llc-612256-02182021","2026-10-26T08:09:53.390359+00:00","2021-02-19","612256","Jason W. Harris","2026-08-20T03:22:28.818+00:00","Via Overnight Delivery","2021-02-18",{"id":201,"raw":202,"subject":14,"body_html":206,"body_text":207,"firm_name":208,"letter_id":209,"created_at":89,"fei_number":20,"letter_url":210,"updated_at":211,"action_type":23,"case_status":24,"posted_date":212,"marcs_cms_no":213,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":214,"body_fetched_at":215,"delivery_method":216,"recipient_title":20,"reference_number":217,"action_taken_date":218,"medical_device_id":20,"response_letter_date":20},336,[203,204,205,11,12,13,13,13],"\u003Ctime datetime=\"2026-02-10T05:00:00Z\">02\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-29T05:00:00Z\">01\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcentral-coast-multispecialty-medical-group-inc-722521-01292026\">Central Coast Multispecialty Medical Group, Inc. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-722521\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Edward J. Ramirez, MD, FACOG\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Executive Medical Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Central Coast Multispecialty Medical Group, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9833 Blue Larkspur Ln\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Monterey\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>93940\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ejrmd@montereybayivf.com\"> ejrmd@montereybayivf.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CBER 26-722521\u003C\u002Fp>\u003Cp>January 29, 2026\u003C\u002Fp>\u003Cp>Dear Dr. Ramirez:\u003C\u002Fp>\u003Cp>During an inspection of your firm, Central Coast Multispecialty Medical Group, Inc., located at 9833 Blue Larkspur Lane, Monterey, CA, conducted between May 13, 2025, and May 16, 2025, the United States Food and Drug Administration (FDA) documented significant violations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (21 CFR) Part 1271 [21 CFR 1271] and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\u003C\u002Fp>\u003Cp>The observations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection, and following FDA’s review, your violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1) &nbsp; Failure to screen a donor of reproductive cells or tissue by reviewing the donor’srelevant medical records for risk factors for, and clinical evidence of, relevantcommunicable disease agents and diseases [21 CFR 1271.75(a)(1)]. Your firm’sDonor Eligibility Questionnaire and Donor Medical History Interview Form areused as relevant medical records to determine donor eligibility. However, yourforms do not include screening for all conditions and\u002For behaviors that increase adonor’s relevant communicable disease risk. For example, the Donor EligibilityQuestionnaire form submitted with your FDA 483 response is missing questions,timeframes, and\u002For deferral periods to assess a donor’s relevant communicabledisease risk for the following:\u003C\u002Fp>\u003Cp>a. Question 5 fails to screen for persons who have had sex in the preceding 12 months with any person who has had sex with a man who has had sex with another man in the preceding 5 years, persons with \u003Cstrong>hepatitis B infection\u003C\u002Fstrong> (both active and inactive) or \u003Cstrong>clinically active (symptomatic)\u003C\u002Fstrong> \u003Cstrong>hepatitis C infection\u003C\u002Fstrong>, persons who have injected drugs for a non-medical reason in the preceding 5 years, including intravenous, intramuscular, or subcutaneous injections, and persons who have engaged in sex in exchange for money or drugs in the preceding 5 years.\u003C\u002Fp>\u003Cp>b. Question 8 states, “Have you within the past 12 months of donation undergone tattoing [sic], ear piercing, or body piercing in which shared instruments are known to have been used.” The question needs to also ask whether sterile procedures were not used.\u003C\u002Fp>\u003Cp>c. Question 11 states, “Have you had a recent smallpox vaccination (vaccinia virus) in the last 21 days?” To adequately and appropriately reduce the risk of transmission of this disease, the question needs to ask about smallpox vaccination (vaccinia virus) in the preceding \u003Cstrong>8 weeks\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>d. Question 13 states, “Have you had a medical diagnosis of West Nile Virus Infection within the last 120 days (including diagnosis based on symptoms and laboratory results, or confirmed WNV viremia)?” You do not include “suspicion” in your form or equivalent terminology to adequately screen for this illness.\u003C\u002Fp>\u003Cp>e. Your form fails to adequately screen for persons who have spent 3 months or more \u003Cstrong>cumulatively\u003C\u002Fstrong> in the UK between 1980 and 1996. Without “cumulatively” or similar language the question is under-inclusive.\u003C\u002Fp>\u003Cp>f. Your form fails to adequately screen for persons who are current or former U.S. military members, civilian military employees, or dependents of a military member or civilian employee who resided at U.S. military bases in Northern Europe (Germany, Belgium, and the Netherlands) for 6 months or more \u003Cstrong>cumulatively\u003C\u002Fstrong> from 1980 through 1990, or elsewhere in Europe (Greece, Turkey, Spain, Portugal, and Italy) for 6 months or more \u003Cstrong>cumulatively\u003C\u002Fstrong> from 1980 through 1996. Without “cumulatively” or similar language the question is under-inclusive.\u003C\u002Fp>\u003Cp>g. Your form fails to screen for persons who spent 5 years or more cumulatively in Europe from 1980 until the present (note this criterion includes time spent in the U.K. from 1980 through 1996).\u003C\u002Fp>\u003Cp>h. Your question 29 states, “Have you had close contact within 12 months preceding donation with another person having clinically active viral hepatitis?” To adequately and appropriately reduce the risk of transmission of this disease, the question needs to also ask about persons who have lived with (resided in the same dwelling) another person who has \u003Cstrong>hepatitis B\u003C\u002Fstrong> or \u003Cstrong>clinically active (symptomatic) hepatitis C\u003C\u002Fstrong> infection in the preceding 12 months.&nbsp;\u003C\u002Fp>\u003Cp>i. Your form fails to screen for persons who have tested positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\u003C\u002Fp>\u003Cp>2) Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1), (b), or (c) [21 CFR 1271.75(d)]. For example, directed semen donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> answered \"yes\" to question 1 on your \u003Cem>Donor Medical History Interview Form\u003C\u002Fem>, “(Men only) Have you had sex with another man in the preceding five years?” Donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> was determined “eligible” on May 9, 2025.\u003C\u002Fp>\u003Cp>3) Failure to determine whether a donor is eligible based upon the results of donor screening in accordance with 21 CFR 1271.75 and donor testing in accordance with 21 CFR 1271.80 and 21 CFR 1271.85 [21 CFR 1271.50(a)]. The eligibility of donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> was determined and documented prior to the receipt of the results of donor testing for relevant communicable disease agents. For example, directed semen donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> was determined “eligible” on May 9, 2025, but the results of donor testing for \u003Cem>Chlamydia trachomatis\u003C\u002Fem>, \u003Cem>Neisseria gonorrhea\u003C\u002Fem>, and HIV\u002FHCV\u002FHBV NAT were not received until May 10, 2025.\u003C\u002Fp>\u003Cp>The violations identified above are not intended to be an all-inclusive list of violations at your facility. It is your responsibility to ensure that your establishment complies with all applicable federal regulations. You are responsible for reviewing your firm’s operations, including firms within the same organization, as a whole to ensure that you are in compliance with the law.\u003C\u002Fp>\u003Cp>Additional information regarding the regulation of HCT\u002FPs is available at:\u003C\u002Fp>\u003Cul>\u003Cli>https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Ftissue-tissue-products\u003C\u002Fli>\u003Cli>https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fbiologics-guidances\u002Ftissue-guidances\u003C\u002Fli>\u003Cli>FDA Workshop for the Reproductive Tissue Industry - Sept 29 and Oct 1, 2020 - 09\u002F29\u002F2020 - 10\u002F01\u002F2020 | FDA\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We acknowledge receipt of your letter, dated May 28, 2025, providing a response to the FDA’s inspectional observations. We have reviewed your response, and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response:\u003C\u002Fp>\u003Cp>1) We acknowledge the revisions made to your Donor Eligibility Questionnaire submitted with your response. However, our review of this questionnaire identified additional deficiencies as outlined in this letter.\u003C\u002Fp>\u003Cp>2) Regarding Observations 1 and 2, your response does not address the required labeling in accordance with 21 CFR 1271.65(b)(2). All donors, except as provided under 21 CFR 1271.90, are required to be screened by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases (21 CFR 1271.75(a)) and tested for relevant communicable diseases (21 CFR 1271.80). Please note, an HCT\u002FP from a donor who has been determined to be ineligible, based on the results of required testing and\u002For screening, is not prohibited by Subpart C from use for implantation, transplantation, infusion, or transfer if the HCT\u002FP consists of reproductive cells or tissue from a directed reproductive donor as defined in 21 CFR 1271.3(l).\u003C\u002Fp>\u003Cp>3) Regarding Observation 3, you stated “The policies and procedures that are in place in regards to our treatment of Donor patients is verbally transmitted through training and continuous guidance, and we do not rely on the Donor policy book for reference or use. It is merely there to be compliant.” Please be advised, you must establish and maintain procedures for all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements of 21 CFR Part 1271, Subpart C. Establish and maintain means define, document (in writing or electronically), and implement; then follow, review, and as needed, revise on an ongoing basis.\u003C\u002Fp>\u003Cp>Please note that if you still have oocytes and\u002For semen in storage from donors whose screening and\u002For testing was not completed in accordance with 21 CFR Part 1271, FDA considers the donor eligibility determinations to be incomplete for these donors. For example, this includes donors who were not appropriately tested for relevant communicable disease agents and diseases and\u002For who were not appropriately screened for relevant communicable disease risk factors which includes using previous versions of donor history questionnaires that did not screen for all conditions and\u002For behaviors that increase a donor’s relevant communicable disease risk. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine.\u003C\u002Fp>\u003Cp>Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may request an exemption or alternative from a requirement in Subpart C, 21 CFR Part 1271, as specified in 21 CFR 1271.155. Additional information can be found at Exemptions and Alternatives | FDA. The email address for submissions is HCTPExemptions@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Please note that 21 CFR 1271.155 requires that you provide justification for use of HCT\u002FPs from these donors, as well as information on how you have mitigated the risk consistent with the goals of protecting the public health and\u002For preventing the introduction, transmission, or spread of communicable diseases. Before any of these HCT\u002FPs can be removed from quarantine, the request must be granted by FDA.\u003C\u002Fp>\u003Cp>If you still have embryos in storage for which the donor eligibility requirements under 21 CFR 1271, Subpart C are not met, please note that FDA considers the donor eligibility determinations to be incomplete for these donors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine. Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may release these HCT\u002FPs from quarantine [21 CFR 1271.90(b)] provided they are labeled in accordance with the applicable regulations at 21 CFR 1271.90(c).\u003C\u002Fp>\u003Cp>You should take prompt action to correct any violations addressed in this letter and prevent their recurrence. Failure to promptly correct any violations may result in regulatory action being initiated by FDA without further notice.\u003C\u002Fp>\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent them, or similar violations, from occurring again. Additionally, include any documentation necessary to show that correction has been achieved. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\u003C\u002Fp>\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>If you have any questions regarding this letter, please contact CBER’s Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Please be advised that only written communications are considered official.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-722521\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nEdward J. Ramirez, MD, FACOG\n\nRecipient Title\n\nExecutive Medical Director\n\nCentral Coast Multispecialty Medical Group, Inc.\n\n9833 Blue Larkspur Ln\n\nMonterey, CA 93940\n\nUnited States\n\nejrmd@montereybayivf.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nCBER 26-722521\nJanuary 29, 2026\nDear Dr. Ramirez:\nDuring an inspection of your firm, Central Coast Multispecialty Medical Group, Inc., located at 9833 Blue Larkspur Lane, Monterey, CA, conducted between May 13, 2025, and May 16, 2025, the United States Food and Drug Administration (FDA) documented significant violations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (21 CFR) Part 1271 [21 CFR 1271] and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\nThe observations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection, and following FDA’s review, your violations include, but are not limited to, the following:\n1) Failure to screen a donor of reproductive cells or tissue by reviewing the donor’srelevant medical records for risk factors for, and clinical evidence of, relevantcommunicable disease agents and diseases [21 CFR 1271.75(a)(1)]. Your firm’sDonor Eligibility Questionnaire and Donor Medical History Interview Form areused as relevant medical records to determine donor eligibility. However, yourforms do not include screening for all conditions and\u002For behaviors that increase adonor’s relevant communicable disease risk. For example, the Donor EligibilityQuestionnaire form submitted with your FDA 483 response is missing questions,timeframes, and\u002For deferral periods to assess a donor’s relevant communicabledisease risk for the following:\na. Question 5 fails to screen for persons who have had sex in the preceding 12 months with any person who has had sex with a man who has had sex with another man in the preceding 5 years, persons with hepatitis B infection (both active and inactive) or clinically active (symptomatic) hepatitis C infection, persons who have injected drugs for a non-medical reason in the preceding 5 years, including intravenous, intramuscular, or subcutaneous injections, and persons who have engaged in sex in exchange for money or drugs in the preceding 5 years.\nb. Question 8 states, “Have you within the past 12 months of donation undergone tattoing [sic], ear piercing, or body piercing in which shared instruments are known to have been used.” The question needs to also ask whether sterile procedures were not used.\nc. Question 11 states, “Have you had a recent smallpox vaccination (vaccinia virus) in the last 21 days?” To adequately and appropriately reduce the risk of transmission of this disease, the question needs to ask about smallpox vaccination (vaccinia virus) in the preceding 8 weeks.\nd. Question 13 states, “Have you had a medical diagnosis of West Nile Virus Infection within the last 120 days (including diagnosis based on symptoms and laboratory results, or confirmed WNV viremia)?” You do not include “suspicion” in your form or equivalent terminology to adequately screen for this illness.\ne. Your form fails to adequately screen for persons who have spent 3 months or more cumulatively in the UK between 1980 and 1996. Without “cumulatively” or similar language the question is under-inclusive.\nf. Your form fails to adequately screen for persons who are current or former U.S. military members, civilian military employees, or dependents of a military member or civilian employee who resided at U.S. military bases in Northern Europe (Germany, Belgium, and the Netherlands) for 6 months or more cumulatively from 1980 through 1990, or elsewhere in Europe (Greece, Turkey, Spain, Portugal, and Italy) for 6 months or more cumulatively from 1980 through 1996. Without “cumulatively” or similar language the question is under-inclusive.\ng. Your form fails to screen for persons who spent 5 years or more cumulatively in Europe from 1980 until the present (note this criterion includes time spent in the U.K. from 1980 through 1996).\nh. Your question 29 states, “Have you had close contact within 12 months preceding donation with another person having clinically active viral hepatitis?” To adequately and appropriately reduce the risk of transmission of this disease, the question needs to also ask about persons who have lived with (resided in the same dwelling) another person who has hepatitis B or clinically active (symptomatic) hepatitis C infection in the preceding 12 months.\ni. Your form fails to screen for persons who have tested positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\n2) Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1), (b), or (c) [21 CFR 1271.75(d)]. For example, directed semen donor (b)(6) answered \"yes\" to question 1 on your Donor Medical History Interview Form, “(Men only) Have you had sex with another man in the preceding five years?” Donor (b)(6) was determined “eligible” on May 9, 2025.\n3) Failure to determine whether a donor is eligible based upon the results of donor screening in accordance with 21 CFR 1271.75 and donor testing in accordance with 21 CFR 1271.80 and 21 CFR 1271.85 [21 CFR 1271.50(a)]. The eligibility of donor (b)(6) was determined and documented prior to the receipt of the results of donor testing for relevant communicable disease agents. For example, directed semen donor (b)(6) was determined “eligible” on May 9, 2025, but the results of donor testing for Chlamydia trachomatis, Neisseria gonorrhea, and HIV\u002FHCV\u002FHBV NAT were not received until May 10, 2025.\nThe violations identified above are not intended to be an all-inclusive list of violations at your facility. It is your responsibility to ensure that your establishment complies with all applicable federal regulations. You are responsible for reviewing your firm’s operations, including firms within the same organization, as a whole to ensure that you are in compliance with the law.\nAdditional information regarding the regulation of HCT\u002FPs is available at:\nhttps:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Ftissue-tissue-products\nhttps:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fbiologics-guidances\u002Ftissue-guidances\nFDA Workshop for the Reproductive Tissue Industry - Sept 29 and Oct 1, 2020 - 09\u002F29\u002F2020 - 10\u002F01\u002F2020 | FDA\nWe acknowledge receipt of your letter, dated May 28, 2025, providing a response to the FDA’s inspectional observations. We have reviewed your response, and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response:\n1) We acknowledge the revisions made to your Donor Eligibility Questionnaire submitted with your response. However, our review of this questionnaire identified additional deficiencies as outlined in this letter.\n2) Regarding Observations 1 and 2, your response does not address the required labeling in accordance with 21 CFR 1271.65(b)(2). All donors, except as provided under 21 CFR 1271.90, are required to be screened by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases (21 CFR 1271.75(a)) and tested for relevant communicable diseases (21 CFR 1271.80). Please note, an HCT\u002FP from a donor who has been determined to be ineligible, based on the results of required testing and\u002For screening, is not prohibited by Subpart C from use for implantation, transplantation, infusion, or transfer if the HCT\u002FP consists of reproductive cells or tissue from a directed reproductive donor as defined in 21 CFR 1271.3(l).\n3) Regarding Observation 3, you stated “The policies and procedures that are in place in regards to our treatment of Donor patients is verbally transmitted through training and continuous guidance, and we do not rely on the Donor policy book for reference or use. It is merely there to be compliant.” Please be advised, you must establish and maintain procedures for all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements of 21 CFR Part 1271, Subpart C. Establish and maintain means define, document (in writing or electronically), and implement; then follow, review, and as needed, revise on an ongoing basis.\nPlease note that if you still have oocytes and\u002For semen in storage from donors whose screening and\u002For testing was not completed in accordance with 21 CFR Part 1271, FDA considers the donor eligibility determinations to be incomplete for these donors. For example, this includes donors who were not appropriately tested for relevant communicable disease agents and diseases and\u002For who were not appropriately screened for relevant communicable disease risk factors which includes using previous versions of donor history questionnaires that did not screen for all conditions and\u002For behaviors that increase a donor’s relevant communicable disease risk. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine.\nShould the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may request an exemption or alternative from a requirement in Subpart C, 21 CFR Part 1271, as specified in 21 CFR 1271.155. Additional information can be found at Exemptions and Alternatives | FDA. The email address for submissions is HCTPExemptions@fda.hhs.gov.\nPlease note that 21 CFR 1271.155 requires that you provide justification for use of HCT\u002FPs from these donors, as well as information on how you have mitigated the risk consistent with the goals of protecting the public health and\u002For preventing the introduction, transmission, or spread of communicable diseases. Before any of these HCT\u002FPs can be removed from quarantine, the request must be granted by FDA.\nIf you still have embryos in storage for which the donor eligibility requirements under 21 CFR 1271, Subpart C are not met, please note that FDA considers the donor eligibility determinations to be incomplete for these donors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine. Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may release these HCT\u002FPs from quarantine [21 CFR 1271.90(b)] provided they are labeled in accordance with the applicable regulations at 21 CFR 1271.90(c).\nYou should take prompt action to correct any violations addressed in this letter and prevent their recurrence. Failure to promptly correct any violations may result in regulatory action being initiated by FDA without further notice.\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent them, or similar violations, from occurring again. Additionally, include any documentation necessary to show that correction has been achieved. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\nYour written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\nIf you have any questions regarding this letter, please contact CBER’s Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Please be advised that only written communications are considered official.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research","Central Coast Multispecialty Medical Group, Inc.","central-coast-multispecialty-medical-group-inc-722521-01292026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcentral-coast-multispecialty-medical-group-inc-722521-01292026","2026-10-26T08:08:13.022809+00:00","2026-02-10","722521","Edward J. Ramirez, MD, FACOG","2026-08-19T04:58:19.54+00:00","Via UPS and EMAIL","CBER 26-722521","2026-01-29",10,{"510k":221,"classification":222,"enforcement":223,"event":224,"event_backfill":225,"pma":226,"warning_letter":227},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]